{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T07:16:30Z","timestamp":1793085390467,"version":"4.5.0"},"reference-count":531,"publisher":"Oxford University Press (OUP)","issue":"7","funder":[{"DOI":"10.13039\/100001465","name":"American Thoracic Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001465","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006292","name":"IDSA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006292","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CDC"},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America jointly sponsored the development of this guideline for the treatment of drug-susceptible tuberculosis, which is also endorsed by the European Respiratory Society and the US National Tuberculosis Controllers Association. Representatives from the American Academy of Pediatrics, the Canadian Thoracic Society, the International Union Against Tuberculosis and Lung Disease, and the World Health Organization also participated in the development of the guideline. This guideline provides recommendations on the clinical and public health management of tuberculosis in children and adults in settings in which mycobacterial cultures, molecular and phenotypic drug susceptibility tests, and radiographic studies, among other diagnostic tools, are available on a routine basis. For all recommendations, literature reviews were performed, followed by discussion by an expert committee according to the Grading of Recommendations, Assessment, Development and Evaluation methodology. Given the public health implications of prompt diagnosis and effective management of tuberculosis, empiric multidrug treatment is initiated in almost all situations in which active tuberculosis is suspected. Additional characteristics such as presence of comorbidities, severity of disease, and response to treatment influence management decisions. Specific recommendations on the use of case management strategies (including directly observed therapy), regimen and dosing selection in adults and children (daily vs intermittent), treatment of tuberculosis in the presence of HIV infection (duration of tuberculosis treatment and timing of initiation of antiretroviral therapy), as well as treatment of extrapulmonary disease (central nervous system, pericardial among other sites) are provided. The development of more potent and better-tolerated drug regimens, optimization of drug exposure for the component drugs, optimal management of tuberculosis in special populations, identification of accurate biomarkers of treatment effect, and the assessment of new strategies for implementing regimens in the field remain key priority areas for research. See the full-text online version of the document for detailed discussion of the management of tuberculosis and recommendations for practice.<\/jats:p>","DOI":"10.1093\/cid\/ciw376","type":"journal-article","created":{"date-parts":[[2016,8,11]],"date-time":"2016-08-11T20:08:35Z","timestamp":1470946115000},"page":"e147-e195","source":"Crossref","is-referenced-by-count":1165,"title":["Official American Thoracic Society\/Centers for Disease Control and Prevention\/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis"],"prefix":"10.1093","volume":"63","author":[{"given":"Payam","family":"Nahid","sequence":"first","affiliation":[{"name":"University 1 \u00a0 \u00a0 , San Francisco"},{"name":"of California 1 \u00a0 \u00a0 , San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan E.","family":"Dorman","sequence":"additional","affiliation":[{"name":"Johns Hopkins University 2 \u00a0 , Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narges","family":"Alipanah","sequence":"additional","affiliation":[{"name":"University 1 \u00a0 \u00a0 , San Francisco"},{"name":"of California 1 \u00a0 \u00a0 , San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pennan M.","family":"Barry","sequence":"additional","affiliation":[{"name":"3 \u00a0California Department of Public Health, Richmond"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan L.","family":"Brozek","sequence":"additional","affiliation":[{"name":"McMaster University 4 \u00a0 , Hamilton, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adithya","family":"Cattamanchi","sequence":"additional","affiliation":[{"name":"University 1 \u00a0 \u00a0 , San Francisco"},{"name":"of California 1 \u00a0 \u00a0 , San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lelia H.","family":"Chaisson","sequence":"additional","affiliation":[{"name":"University 1 \u00a0 \u00a0 , San Francisco"},{"name":"of California 1 \u00a0 \u00a0 , San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E.","family":"Chaisson","sequence":"additional","affiliation":[{"name":"Johns Hopkins University 2 \u00a0 , Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles L.","family":"Daley","sequence":"additional","affiliation":[{"name":"National Jewish Health 5 \u00a0 , Denver, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malgosia","family":"Grzemska","sequence":"additional","affiliation":[{"name":"World Health Organization 6 \u00a0 , Geneva , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie M.","family":"Higashi","sequence":"additional","affiliation":[{"name":"Tuberculosis Control Section 7 \u00a0 , San Francisco Department of Public Health, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine S.","family":"Ho","sequence":"additional","affiliation":[{"name":"National Center for HIV\/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention 8 \u00a0 Division of Tuberculosis Elimination , , Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip C.","family":"Hopewell","sequence":"additional","affiliation":[{"name":"University 1 \u00a0 \u00a0 , San Francisco"},{"name":"of California 1 \u00a0 \u00a0 , San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salmaan A.","family":"Keshavjee","sequence":"additional","affiliation":[{"name":"Harvard Medical School 9 \u00a0 , Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Lienhardt","sequence":"additional","affiliation":[{"name":"World Health Organization 6 \u00a0 , Geneva , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Menzies","sequence":"additional","affiliation":[{"name":"McGill University 10 \u00a0 , Montreal, Quebec , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Merrifield","sequence":"additional","affiliation":[{"name":"University 1 \u00a0 \u00a0 , San Francisco"},{"name":"of California 1 \u00a0 \u00a0 , San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Narita","sequence":"additional","affiliation":[{"name":"Tuberculosis Control Program, Seattle and King County Public Health, and University of Washington 12 \u00a0 , Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rick","family":"O'Brien","sequence":"additional","affiliation":[{"name":"International Union Against TB and Lung Disease 13 \u00a0 Ethics Advisory Group , , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles A.","family":"Peloquin","sequence":"additional","affiliation":[{"name":"University of Florida 14 \u00a0 , Gainesville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Raftery","sequence":"additional","affiliation":[{"name":"University 1 \u00a0 \u00a0 , San Francisco"},{"name":"of California 1 \u00a0 \u00a0 , San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jussi","family":"Saukkonen","sequence":"additional","affiliation":[{"name":"Boston University 15 \u00a0 , Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Simon","family":"Schaaf","sequence":"additional","affiliation":[{"name":"16 \u00a0Department of Paediatrics and Child Health, Stellenbosch University, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Sotgiu","sequence":"additional","affiliation":[{"name":"University of Sassari 17 \u00a0 , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey R.","family":"Starke","sequence":"additional","affiliation":[{"name":"Baylor College of Medicine 18 \u00a0 , Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni Battista","family":"Migliori","sequence":"additional","affiliation":[{"name":"11 \u00a0WHO Collaborating Centre for TB and Lung Diseases, Fondazione S. Maugeri Care and Research Institute, Tradate, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Vernon","sequence":"additional","affiliation":[{"name":"National Center for HIV\/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention 8 \u00a0 Division of Tuberculosis Elimination , , Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,8,10]]},"reference":[{"key":"2024062808202669200_CIW376C1","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1164\/rccm.200602-197ST","article-title":"An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations","volume":"174","author":"Schunemann","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"2024062808202669200_CIW376C2","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"10 suppl 2","key":"2024062808202669200_CIW376C3","first-page":"S231","article-title":"Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946\u20131986, with relevant subsequent publications","volume":"3","author":"Fox","year":"1999","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024062808202669200_CIW376C4","doi-asserted-by":"crossref","first-page":"724","DOI":"10.5588\/ijtld.12.0083","article-title":"The chemotherapy of tuberculosis: past, present and future","volume":"16","author":"Mitchison","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024062808202669200_CIW376C5","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa1407426","article-title":"Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis","volume":"371","author":"Gillespie","year":"2014","journal-title":"N Engl J Med"},{"key":"2024062808202669200_CIW376C6","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0041-3879(80)90060-4","article-title":"Side-effects of drug regimens used in short-course chemotherapy for pulmonary tuberculosis. A controlled clinical study","volume":"61","author":"Zierski","year":"1980","journal-title":"Tubercle"},{"key":"2024062808202669200_CIW376C7","doi-asserted-by":"crossref","first-page":"e63840","DOI":"10.1371\/journal.pone.0063840","article-title":"An evaluation of culture results during treatment for tuberculosis as surrogate endpoints for treatment failure and relapse","volume":"8","author":"Phillips","year":"2013","journal-title":"PLoS One"},{"key":"2024062808202669200_CIW376C8","first-page":"276","article-title":"Short term chemotherapy of tuberculosis. Factors affecting relapse following short term chemotherapy [in French]","volume":"53","author":"Aber","year":"1978","journal-title":"Bull Int Union Tuberc"},{"key":"2024062808202669200_CIW376C9","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S0140-6736(02)09742-8","article-title":"Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial","volume":"360","author":"Benator","year":"2002","journal-title":"Lancet"},{"key":"2024062808202669200_CIW376C10","volume-title":"Treatment of tuberculosis disease. Canadian Tuberculosis Standards","author":"Menzies","year":"2014","edition":"7th ed"},{"key":"2024062808202669200_CIW376C11","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1164\/rccm.200208-951OC","article-title":"Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine","volume":"167","author":"Weiner","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"issue":"RR-11","key":"2024062808202669200_CIW376C12","first-page":"1","article-title":"Recommendations of the Advisory Council for the Elimination of Tuberculosis","volume":"44","author":"Essential components of a tuberculosis prevention and control program","year":"1995","journal-title":"MMWR Recomm Rep"},{"issue":"RR-12","key":"2024062808202669200_CIW376C13","first-page":"1","article-title":"Controlling tuberculosis in the United States. Recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America","volume":"54","author":"Taylor","year":"2005","journal-title":"MMWR Recomm Rep"},{"key":"2024062808202669200_CIW376C14","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/S1473-3099(06)70628-4","article-title":"International standards for tuberculosis care","volume":"6","author":"Hopewell","year":"2006","journal-title":"Lancet Infect Dis"},{"key":"2024062808202669200_CIW376C15","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1183\/09031936.00203811","article-title":"European Union standards for tuberculosis care","volume":"39","author":"Migliori","year":"2012","journal-title":"Eur Respir J"},{"key":"2024062808202669200_CIW376C16","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1513\/AnnalsATS.201401-004AR","article-title":"Updating the International Standards for Tuberculosis Care. Entering the era of molecular diagnostics","volume":"11","author":"Hopewell","year":"2014","journal-title":"Ann Am Thorac Soc"},{"key":"2024062808202669200_CIW376C17","article-title":"Managing tuberculosis patients and improving adherence","author":"Centers for Disease Control and Prevention","year":"2014"},{"key":"2024062808202669200_CIW376C18","doi-asserted-by":"crossref","first-page":"e238","DOI":"10.1371\/journal.pmed.0040238","article-title":"Patient adherence to tuberculosis treatment: a systematic review of qualitative research","volume":"4","author":"Munro","year":"2007","journal-title":"PLoS Med"},{"key":"2024062808202669200_CIW376C19","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/00129234-200211000-00005","article-title":"A ten-step process to develop case management plans","volume":"7","author":"Tahan","year":"2002","journal-title":"Lippincotts Case Manag"},{"key":"2024062808202669200_CIW376C20","doi-asserted-by":"crossref","first-page":"404","DOI":"10.2471\/BLT.06.035568","article-title":"Promoting adherence to tuberculosis treatment","volume":"85","author":"Garner","year":"2007","journal-title":"Bull World Health Organ"},{"key":"2024062808202669200_CIW376C21","doi-asserted-by":"crossref","first-page":"497","DOI":"10.2146\/ajhp050543","article-title":"Effect of pharmacist-led patient education on adherence to tuberculosis treatment","volume":"64","author":"Clark","year":"2007","journal-title":"Am J Health Syst Pharm"},{"key":"2024062808202669200_CIW376C22","first-page":"1073","article-title":"A randomised trial of the impact of counselling on treatment adherence of tuberculosis patients in Sialkot, Pakistan","volume":"3","author":"Liefooghe","year":"1999","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024062808202669200_CIW376C23","first-page":"CD006591","article-title":"Patient education and counselling for promoting adherence to treatment for tuberculosis","volume":"5","author":"M'Imunya","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"2024062808202669200_CIW376C24","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1177\/1077558705275416","article-title":"The impact of medical interpreter services on the quality of health care: a systematic review","volume":"62","author":"Flores","year":"2005","journal-title":"Med Care Res Rev"},{"key":"2024062808202669200_CIW376C25","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0041-3879(81)90017-9","article-title":"A randomised study of two policies for managing default in out-patients collecting supplies of drugs for pulmonary tuberculosis in a large city in South India","volume":"62","author":"Krishnaswami","year":"1981","journal-title":"Tubercle"},{"key":"2024062808202669200_CIW376C26","first-page":"1444","article-title":"Tuberculosis treatment with mobile-phone medication reminders in northern Thailand","volume":"42","author":"Kunawararak","year":"2011","journal-title":"Southeast Asian J Trop Med Public Health"},{"key":"2024062808202669200_CIW376C27","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/00005650-199404000-00006","article-title":"Automated telephone reminders in tuberculosis care","volume":"32","author":"Tanke","year":"1994","journal-title":"Med Care"},{"key":"2024062808202669200_CIW376C28","first-page":"CD006594","article-title":"Reminder systems to improve patient adherence to tuberculosis clinic appointments for diagnosis and treatment","volume":"11","author":"Liu","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2024062808202669200_CIW376C29","first-page":"349394","article-title":"TextTB: a mixed method pilot study evaluating acceptance, feasibility, and exploring initial efficacy of a text messaging intervention to support TB treatment adherence","volume":"2013","author":"Iribarren","year":"2013","journal-title":"Tuberc Res Treat"},{"key":"2024062808202669200_CIW376C30","first-page":"CD007952","article-title":"Material incentives and enablers in the management of tuberculosis","volume":"1","author":"Lutge","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"2024062808202669200_CIW376C31","doi-asserted-by":"crossref","first-page":"b4248","DOI":"10.1136\/bmj.b4248","article-title":"Food incentives to improve completion of tuberculosis treatment: randomised controlled trial in Dili, Timor-Leste","volume":"339","author":"Martins","year":"2009","journal-title":"BMJ"},{"key":"2024062808202669200_CIW376C32","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s12879-015-0945-5","article-title":"Community-based directly observed therapy (DOT) versus clinic DOT for tuberculosis: a systematic review and meta-analysis of comparative effectiveness","volume":"15","author":"Wright","year":"2015","journal-title":"BMC Infect Dis"},{"key":"2024062808202669200_CIW376C33","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1001\/jama.279.12.943","article-title":"Directly observed therapy for treatment completion of pulmonary tuberculosis: consensus statement of the Public Health Tuberculosis Guidelines Panel","volume":"279","author":"Chaulk","year":"1998","journal-title":"JAMA"},{"key":"2024062808202669200_CIW376C34","first-page":"884","article-title":"DOT and timely treatment completion among Asian-born immigrant tuberculosis patients","volume":"9","author":"Liu","year":"2005","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024062808202669200_CIW376C35","article-title":"A call for action on the tuberculosis elimination plan for the United States","author":"Stop TB USA Tuberculosis Elimination Plan Committee","year":"2010"},{"key":"2024062808202669200_CIW376C36","doi-asserted-by":"crossref","first-page":"e1000146","DOI":"10.1371\/journal.pmed.1000146","article-title":"Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis","volume":"6","author":"Menzies","year":"2009","journal-title":"PLoS Med"},{"key":"2024062808202669200_CIW376C37","doi-asserted-by":"crossref","first-page":"e1000150","DOI":"10.1371\/journal.pmed.1000150","article-title":"Standardized treatment of active tuberculosis in patients with previous treatment and\/or with mono-resistance to isoniazid: a systematic review and meta-analysis","volume":"6","author":"Menzies","year":"2009","journal-title":"PLoS Med"},{"key":"2024062808202669200_CIW376C38","first-page":"501","article-title":"Isoniazid- and rifampin-resistant tuberculosis in San Diego County, California, United States, 1993\u20132002","volume":"9","author":"LoBue","year":"2005","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024062808202669200_CIW376C39","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1001\/archinte.168.18.1984","article-title":"Isoniazid-monoresistant tuberculosis in the United States, 1993 to 2003","volume":"168","author":"Hoopes","year":"2008","journal-title":"Arch Intern Med"},{"key":"2024062808202669200_CIW376C40","doi-asserted-by":"crossref","first-page":"e22927","DOI":"10.1371\/journal.pone.0022927","article-title":"Quantifying the burden and trends of isoniazid resistant tuberculosis, 1994\u20132009","volume":"6","author":"Jenkins","year":"2011","journal-title":"PLoS One"},{"key":"2024062808202669200_CIW376C41","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1542\/peds.2015-0172","article-title":"Global and regional burden of isoniazid-resistant tuberculosis","volume":"136","author":"Yuen","year":"2015","journal-title":"Pediatrics"},{"key":"2024062808202669200_CIW376C42","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0041-3879(80)90038-0","article-title":"Pyridoxine supplementation during isoniazid therapy","volume":"61","author":"Snider","year":"1980","journal-title":"Tubercle"},{"key":"2024062808202669200_CIW376C43","first-page":"260","article-title":"The short-term effects of anti-tuberculosis therapy on plasma pyridoxine levels in patients with pulmonary tuberculosis","volume":"8","author":"Visser","year":"2004","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024062808202669200_CIW376C44","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1164\/ajrccm\/147.4.1062","article-title":"Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months","volume":"147","author":"Mitchison","year":"1993","journal-title":"Am Rev Respir Dis"},{"key":"2024062808202669200_CIW376C45","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.rmed.2014.01.010","article-title":"Risk factors for 1-year relapse of pulmonary tuberculosis treated with a 6-month daily regimen","volume":"108","author":"Jo","year":"2014","journal-title":"Respir Med"},{"key":"2024062808202669200_CIW376C46","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S1473-3099(10)70071-2","article-title":"Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis","volume":"10","author":"Horne","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"2024062808202669200_CIW376C47","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1164\/rccm.200407-905OC","article-title":"A nested case-control study on treatment-related risk factors for early relapse of tuberculosis","volume":"170","author":"Chang","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"2024062808202669200_CIW376C48","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1164\/rccm.200511-1834OC","article-title":"Lack of weight gain and relapse risk in a large tuberculosis treatment trial","volume":"174","author":"Khan","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"2024062808202669200_CIW376C49","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/1741-7015-9-81","article-title":"The impact of diabetes on tuberculosis treatment outcomes: a systematic review","volume":"9","author":"Baker","year":"2011","journal-title":"BMC Med"},{"key":"2024062808202669200_CIW376C50","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1378\/chest.14-0918","article-title":"Optimal duration of anti-TB treatment in patients with diabetes: nine or six months?","volume":"147","author":"Wang","year":"2015","journal-title":"Chest"},{"key":"2024062808202669200_CIW376C51","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1183\/09031936.00114214","article-title":"Smoking adversely affects treatment response, outcome and relapse in tuberculosis","volume":"45","author":"Leung","year":"2015","journal-title":"Eur Respir J"},{"key":"2024062808202669200_CIW376C52","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1093\/cid\/cis630","article-title":"An updated systematic review and meta-analysis on the treatment of active tuberculosis in patients with HIV infection","volume":"55","author":"Ahmad Khan","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2024062808202669200_CIW376C53","volume-title":"Core curriculum on tuberculosis: what the clinician should know.","author":"Centers for Disease Control and Prevention","year":"2013","edition":"6th ed"},{"key":"2024062808202669200_CIW376C54","first-page":"806","article-title":"Impact of food and antacids on the pharmacokinetics of anti-tuberculosis drugs: systematic review and meta-analysis","volume":"14","author":"Lin","year":"2010","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024062808202669200_CIW376C55","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMra052270","article-title":"Drug-related hepatotoxicity","volume":"354","author":"Navarro","year":"2006","journal-title":"N Engl J Med"},{"key":"2024062808202669200_CIW376C56","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1164\/rccm.200510-1666ST","article-title":"An official ATS statement: hepatotoxicity of antituberculosis therapy","volume":"174","author":"Saukkonen","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"2024062808202669200_CIW376C57","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1086\/650576","article-title":"Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity","volume":"50","author":"Sharma","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2024062808202669200_CIW376C58","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1086\/654806","article-title":"The best approach to reintroducing tuberculosis treatment after hepatotoxicity is still open to debate","volume":"51","author":"Chang","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2024062808202669200_CIW376C59","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/S0140-6736(98)11467-8","article-title":"Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium","volume":"353","author":"Vernon","year":"1999","journal-title":"Lancet"},{"key":"2024062808202669200_CIW376C60","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1164\/rccm.200503-417OC","article-title":"Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis","volume":"173","author":"Burman","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"2024062808202669200_CIW376C61","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1086\/429321","article-title":"Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis","volume":"40","author":"Weiner","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2024062808202669200_CIW376C62","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1093\/cid\/ciu674","article-title":"Acquired rifampicin resistance in thrice-weekly antituberculosis therapy: impact of HIV and antiretroviral therapy","volume":"59","author":"Narendran","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2024062808202669200_CIW376C63","doi-asserted-by":"crossref","first-page":"a257","DOI":"10.1136\/bmj.a257","article-title":"Role of co-trimoxazole prophylaxis in reducing mortality in HIV infected adults being treated for tuberculosis: randomised clinical trial","volume":"337","author":"Nunn","year":"2008","journal-title":"BMJ"},{"key":"2024062808202669200_CIW376C64","doi-asserted-by":"crossref","first-page":"128C","DOI":"10.2471\/BLT.11.093260","article-title":"Effect of cotrimoxazole on mortality in HIV-infected adults on antiretroviral therapy: a systematic review and meta-analysis","volume":"90","author":"Suthar","year":"2012","journal-title":"Bull World Health Organ"},{"key":"2024062808202669200_CIW376C65","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/S0140-6736(99)03465-0","article-title":"Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Cote d'Ivoire: a randomised controlled trial","volume":"353","author":"Wiktor","year":"1999","journal-title":"Lancet"},{"key":"2024062808202669200_CIW376C66","article-title":"Guidelines on post-exposure prophylaxis for HIV and the use of co-trimoxazole prophylaxis for HIV-related infections among adults, adolescents and children: recommendations for a public health approach: December 2014 supplement to the 2013 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection","year":"2014"},{"key":"2024062808202669200_CIW376C67","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1093\/cid\/ciu094","article-title":"Prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: updated Guidelines from the Centers for Disease Control and Prevention, National Institutes of Health, and HIV Medicine Association of the Infectious Diseases Society of America","volume":"58","author":"Masur","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2024062808202669200_CIW376C68","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/QAI.0000000000000030","article-title":"Tuberculosis immune reconstitution inflammatory syndrome in A5221 STRIDE: timing, severity, and implications for HIV-TB programs","volume":"65","author":"Luetkemeyer","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2024062808202669200_CIW376C69","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S1473-3099(08)70184-1","article-title":"Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings","volume":"8","author":"Meintjes","year":"2008","journal-title":"Lancet Infect Dis"},{"key":"2024062808202669200_CIW376C70","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1097\/QAD.0b013e32833dfc68","article-title":"Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome","volume":"24","author":"Meintjes","year":"2010","journal-title":"AIDS"},{"key":"2024062808202669200_CIW376C71","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/S0140-6736(87)91127-5","article-title":"Controlled trial of prednisolone as adjuvant in treatment of tuberculous constrictive pericarditis in Transkei","volume":"2","author":"Strang","year":"1987","journal-title":"Lancet"},{"key":"2024062808202669200_CIW376C72","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(88)92415-4","article-title":"Controlled clinical trial of complete open surgical drainage and of prednisolone in treatment of tuberculous pericardial effusion in Transkei","volume":"2","author":"Strang","year":"1988","journal-title":"Lancet"},{"key":"2024062808202669200_CIW376C73","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1136\/heart.84.2.183","article-title":"Double blind randomised placebo controlled trial of adjunctive prednisolone in the treatment of effusive tuberculous pericarditis in HIV seropositive patients","volume":"84","author":"Hakim","year":"2000","journal-title":"Heart"},{"key":"2024062808202669200_CIW376C74","first-page":"2534","article-title":"Immunotherapy for tuberculous pericarditis","volume":"371","author":"Mayosi","year":"2014","journal-title":"N Engl J Med"},{"key":"2024062808202669200_CIW376C75","first-page":"233","article-title":"Experience with adjunctive corticosteroids in managing tuberculous pericarditis","volume":"17","author":"Reuter","year":"2006","journal-title":"Cardiovasc J S Afr"},{"key":"2024062808202669200_CIW376C76","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1056\/NEJMe1409356","article-title":"Immunotherapy for tuberculous pericarditis","volume":"371","author":"Chaisson","year":"2014","journal-title":"N Engl J Med"},{"key":"2024062808202669200_CIW376C77","article-title":"2015 Red Book: Report of the Committee on Infectious Diseases","author":"American Academy of Pediatrics. Committee on Infectious Diseases","year":"2015","edition":"30th ed"},{"key":"2024062808202669200_CIW376C78","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jinf.2009.06.011","article-title":"British Infection Society guidelines for the diagnosis and treatment of tuberculosis of the central nervous system in adults and children","volume":"59","author":"Thwaites","year":"2009","journal-title":"J Infect"},{"key":"2024062808202669200_CIW376C79","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0140-6736(55)90003-9","article-title":"Tuberculous meningitis treated with cortisone","volume":"268","author":"Ashby","year":"1955","journal-title":"Lancet"},{"key":"2024062808202669200_CIW376C80","doi-asserted-by":"crossref","first-page":"39","DOI":"10.7326\/0003-4819-70-1-39","article-title":"Dexamethasone in tuberculous meningitis. Relationship of cerebrospinal fluid effects to therapeutic efficacy","volume":"70","author":"O'Toole","year":"1969","journal-title":"Ann Intern Med"},{"key":"2024062808202669200_CIW376C81","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1542\/peds.56.6.1050","article-title":"Mortality from tuberculous meningitis reduced by steroid therapy","volume":"56","author":"Escobar","year":"1975","journal-title":"Pediatrics"},{"key":"2024062808202669200_CIW376C82","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/0035-9203(83)90195-5","article-title":"The use of dexamethasone in preventing ocular complications in tuberculous meningitis","volume":"77","author":"Girgis","year":"1983","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2024062808202669200_CIW376C83","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/00006454-199103000-00002","article-title":"Dexamethasone adjunctive treatment for tuberculous meningitis","volume":"10","author":"Girgis","year":"1991","journal-title":"Pediatr Infect Dis J"},{"key":"2024062808202669200_CIW376C84","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0962-8479(94)90009-4","article-title":"Randomized controlled trial of dexamethasone in tuberculous meningitis","volume":"75","author":"Kumarvelu","year":"1994","journal-title":"Tuber Lung Dis"},{"key":"2024062808202669200_CIW376C85","first-page":"83","article-title":"Corticosteroid in tuberculous meningitis","volume":"79","author":"Chotmongkol","year":"1996","journal-title":"J Med Assoc Thai"},{"key":"2024062808202669200_CIW376C86","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1086\/515543","article-title":"Adjunctive corticosteroid therapy for tuberculosis: a critical reappraisal of the literature","volume":"25","author":"Dooley","year":"1997","journal-title":"Clin Infect Dis"},{"key":"2024062808202669200_CIW376C87","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1542\/peds.99.2.226","article-title":"Effect of corticosteroids on intracranial pressure, computed tomographic findings, and clinical outcome in young children with tuberculous meningitis","volume":"99","author":"Schoeman","year":"1997","journal-title":"Pediatrics"},{"key":"2024062808202669200_CIW376C88","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1056\/NEJMoa040573","article-title":"Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults","volume":"351","author":"Thwaites","year":"2004","journal-title":"N Engl J Med"},{"key":"2024062808202669200_CIW376C89","first-page":"CD002244","article-title":"Corticosteroids for managing tuberculous meningitis","author":"Prasad","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"2024062808202669200_CIW376C90","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1179\/000349809X12502035776315","article-title":"Corticosteroids (dexamethasone versus intravenous methylprednisolone) in patients with tuberculous meningitis","volume":"103","author":"Malhotra","year":"2009","journal-title":"Ann Trop Med Parasitol"},{"key":"2024062808202669200_CIW376C91","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1473-3099(12)70321-3","article-title":"Corticosteroids for prevention of mortality in people with tuberculosis: a systematic review and meta-analysis","volume":"13","author":"Critchley","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"2024062808202669200_CIW376C92","doi-asserted-by":"crossref","first-page":"537","DOI":"10.5588\/ijtld.14.0798","article-title":"The impact of sputum quality on tuberculosis diagnosis: a systematic review","volume":"19","author":"Ho","year":"2015","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024062808202669200_CIW376C93","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1164\/ajrccm\/139.5.1090","article-title":"Presumptive diagnosis and treatment of pulmonary tuberculosis based on radiographic findings","volume":"139","author":"Gordin","year":"1989","journal-title":"Am Rev Respir Dis"},{"issue":"RR-11","key":"2024062808202669200_CIW376C94","first-page":"1","article-title":"Treatment of tuberculosis","volume":"52","author":"American Thoracic Society; Centers for Disease Control and Prevention; Infectious Diseases Society of America","year":"2003","journal-title":"MMWR Recomm Rep"},{"key":"2024062808202669200_CIW376C95","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMra1200894","article-title":"Tuberculosis","volume":"368","author":"Zumla","year":"2013","journal-title":"N Engl J Med"},{"key":"2024062808202669200_CIW376C96","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1183\/09031936.00198813","article-title":"Tuberculosis elimination: theory and practice in Europe","volume":"43","author":"D'Ambrosio","year":"2014","journal-title":"Eur Respir J"},{"key":"2024062808202669200_CIW376C97","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1183\/09031936.00214014","article-title":"Towards tuberculosis elimination: an action framework for low-incidence countries","volume":"45","author":"Lonnroth","year":"2015","journal-title":"Eur Respir J"},{"key":"2024062808202669200_CIW376C98"},{"key":"2024062808202669200_CIW376C99","first-page":"6","article-title":"The curious characteristics of pyrazinamide: a review","volume":"7","author":"Zhang","year":"2003","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024062808202669200_CIW376C100","doi-asserted-by":"crossref","first-page":"e17601","DOI":"10.1371\/journal.pone.0017601","article-title":"Natural history of tuberculosis: duration and fatality of untreated pulmonary tuberculosis in HIV negative patients: a systematic review","volume":"6","author":"Tiemersma","year":"2011","journal-title":"PLoS One"},{"key":"2024062808202669200_CIW376C101","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0041-3879(77)90032-0","article-title":"Tuberculosis in Tanzania: a follow-up of a national sampling survey of drug resistance and other factors","volume":"58","year":"1977","journal-title":"Tubercle"},{"key":"2024062808202669200_CIW376C102","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.5588\/ijtld.13.0834","article-title":"Rapid impact of effective treatment on transmission of multidrug-resistant tuberculosis","volume":"18","author":"Dharmadhikari","year":"2014","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024062808202669200_CIW376C103","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1086\/655127","article-title":"Prolonged infectiousness of tuberculosis patients in a directly observed therapy short-course program with standardized therapy","volume":"51","author":"Fitzwater","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2024062808202669200_CIW376C104","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1086\/513772","article-title":"Factors influencing time to sputum conversion among patients with smear-positive pulmonary tuberculosis","volume":"25","author":"Telzak","year":"1997","journal-title":"Clin Infect Dis"},{"key":"2024062808202669200_CIW376C105","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1086\/502145","article-title":"Relative versus absolute noncontagiousness of respiratory tuberculosis on treatment","volume":"24","author":"Long","year":"2003","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2024062808202669200_CIW376C106","first-page":"939","article-title":"The early bactericidal activity of drugs in patients with pulmonary tuberculosis","volume":"121","author":"Jindani","year":"1980","journal-title":"Am Rev Respir Dis"},{"key":"2024062808202669200_CIW376C107","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1164\/rccm.200210-1125OC","article-title":"Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days","volume":"167","author":"Jindani","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"2024062808202669200_CIW376C108","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1586\/14787210.2014.870884","article-title":"The early bactericidal activity of antituberculosis drugs","volume":"12","author":"Diacon","year":"2014","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2024062808202669200_CIW376C109","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/nrd4001","article-title":"Advances in the development of new tuberculosis drugs and treatment regimens","volume":"12","author":"Zumla","year":"2013","journal-title":"Nat Rev Drug Discov"},{"key":"2024062808202669200_CIW376C110","doi-asserted-by":"crossref","first-page":"6358","DOI":"10.1128\/JB.182.22.6358-6365.2000","article-title":"Detection of mRNA transcripts and active transcription in persistent Mycobacterium tuberculosis induced by exposure to rifampin or pyrazinamide","volume":"182","author":"Hu","year":"2000","journal-title":"J Bacteriol"},{"key":"2024062808202669200_CIW376C111","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1086\/424849","article-title":"Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling","volume":"190","author":"Gumbo","year":"2004","journal-title":"J Infect Dis"},{"key":"2024062808202669200_CIW376C112","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1055\/s-0028-1085705","article-title":"Using animal models to develop new treatments for tuberculosis","volume":"29","author":"Nuermberger","year":"2008","journal-title":"Semin Respir Crit Care Med"},{"key":"2024062808202669200_CIW376C113","volume-title":"The tubercle bacillus in the pulmonary lesion of man; histobacteriology and its bearing on the therapy of pulmonary tuberculosis","author":"Canetti","year":"1955"},{"key":"2024062808202669200_CIW376C114","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1126\/science.1184784","article-title":"Tuberculosis: what we don't know can, and does, hurt us","volume":"328","author":"Russell","year":"2010","journal-title":"Science"},{"key":"2024062808202669200_CIW376C115","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/imr.12252","article-title":"Heterogeneity in tuberculosis pathology, microenvironments and therapeutic responses","volume":"264","author":"Lenaerts","year":"2015","journal-title":"Immunol Rev"},{"key":"2024062808202669200_CIW376C116","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/nrmicro3200","article-title":"The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells","volume":"12","author":"Dartois","year":"2014","journal-title":"Nat Rev Microbiol"},{"key":"2024062808202669200_CIW376C117","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1128\/AAC.00379-15","article-title":"Cavitary penetration of levofloxacin among patients with multidrug-resistant tuberculosis","volume":"59","author":"Kempker","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2024062808202669200_CIW376C118","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1021\/ac1029049","article-title":"High-sensitivity MALDI-MRM-MS imaging of moxifloxacin distribution in tuberculosis-infected rabbit lungs and granulomatous lesions","volume":"83","author":"Prideaux","year":"2011","journal-title":"Anal Chem"},{"key":"2024062808202669200_CIW376C119","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/nm.3937","article-title":"The association between sterilizing activity and drug distribution into tuberculosis lesions","volume":"21","author":"Prideaux","year":"2015","journal-title":"Nat Med"},{"key":"2024062808202669200_CIW376C120","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.5588\/ijtld.15.0389","article-title":"Mechanisms of drug resistance in Mycobacterium tuberculosis: update 2015","volume":"19","author":"Zhang","year":"2015","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024062808202669200_CIW376C121","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1128\/am.20.5.810-814.1970","article-title":"Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis","volume":"20","author":"David","year":"1970","journal-title":"Appl Microbiol"},{"key":"2024062808202669200_CIW376C122","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1164\/rccm.2409005","article-title":"In the treatment of tuberculosis, you get what you pay for","volume":"170","author":"Vernon","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"2024062808202669200_CIW376C123","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/j.1745-7599.2008.00360.x","article-title":"Patient-centered care and adherence: definitions and applications to improve outcomes","volume":"20","author":"Robinson","year":"2008","journal-title":"J Am Acad Nurse Pract"},{"key":"2024062808202669200_CIW376C124","article-title":"Patient centered approach","author":"TB CARE."},{"key":"2024062808202669200_CIW376C125","article-title":"Crossing the quality chasm: a new health system for the 21st century","author":"Institute of Medicine","year":"2001"},{"key":"2024062808202669200_CIW376C126","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1056\/NEJM199902043400506","article-title":"The use of legal action in New York City to ensure treatment of tuberculosis","volume":"340","author":"Gasner","year":"1999","journal-title":"N Engl J Med"},{"key":"2024062808202669200_CIW376C127","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1378\/chest.13-0324","article-title":"Risk factors for and outcomes of detention of patients with TB in New York City: an update: 2002\u20132009","volume":"145","author":"Pursnani","year":"2014","journal-title":"Chest"},{"key":"2024062808202669200_CIW376C128","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/01.XEB.0000444614.17658.46","article-title":"Strategies to promote adherence to treatment by pulmonary tuberculosis patients: a systematic review","volume":"12","author":"Suwankeeree","year":"2014","journal-title":"Int J Evid Based Healthc"},{"key":"2024062808202669200_CIW376C129","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/j.1365-3156.2004.01273.x","article-title":"Tuberculosis control in resource-poor countries: have we reached the limits of the universal paradigm?","volume":"9","author":"Lienhardt","year":"2004","journal-title":"Trop Med Int Health"},{"key":"2024062808202669200_CIW376C130","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1378\/chest.111.5.1168","article-title":"Noncompliance with directly observed therapy for tuberculosis. Epidemiology and effect on the outcome of treatment","volume":"111","author":"Burman","year":"1997","journal-title":"Chest"},{"key":"2024062808202669200_CIW376C131","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1183\/09031936.00011015","article-title":"Video directly observed therapy for treatment of tuberculosis is patient-oriented and cost-effective","volume":"46","author":"Mirsaeidi","year":"2015","journal-title":"Eur Respir J"},{"key":"2024062808202669200_CIW376C132","first-page":"779","article-title":"Videophone utilization as an alternative to directly observed therapy for tuberculosis","volume":"14","author":"Krueger","year":"2010","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024062808202669200_CIW376C133","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.amepre.2010.02.018","article-title":"Mobile direct observation treatment for tuberculosis patients: a technical feasibility pilot using mobile phones in Nairobi, Kenya","volume":"39","author":"Hoffman","year":"2010","journal-title":"Am J Prev Med"},{"key":"2024062808202669200_CIW376C134","first-page":"CD003343","article-title":"Directly observed therapy for treating tuberculosis","author":"Volmink","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"2024062808202669200_CIW376C135","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/cid\/cit167","article-title":"A meta-analysis of self-administered vs directly observed therapy effect on microbiologic failure, relapse, and acquired drug resistance in tuberculosis patients","volume":"57","author":"Pasipanodya","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2024062808202669200_CIW376C136","first-page":"CD003343","article-title":"Directly observed therapy for treating tuberculosis","volume":"5","author":"Karumbi","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2024062808202669200_CIW376C137","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1471-2458-11-19","article-title":"Does directly observed therapy (DOT) reduce drug resistant tuberculosis?","volume":"11","author":"Moonan","year":"2011","journal-title":"BMC Public Health"},{"key":"2024062808202669200_CIW376C138","first-page":"1613","article-title":"Achieving international targets for tuberculosis treatment success among HIV-positive patients in New York City","volume":"14","author":"King","year":"2010","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024062808202669200_CIW376C139","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s10900-006-9036-2","article-title":"Treatment completion among TB patients returned to the community from a large urban jail","volume":"32","author":"Kim","year":"2007","journal-title":"J Community Health"},{"key":"2024062808202669200_CIW376C140","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.5588\/ijtld.14.0776","article-title":"Directly observed therapy of tuberculosis in Brazil: associated determinants and impact on treatment outcome","volume":"19","author":"Reis-Santos","year":"2015","journal-title":"Int J Tuberc Lung Dis"},{"issue":"4 pt 1","key":"2024062808202669200_CIW376C141","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1164\/ajrccm.157.4.9708058","article-title":"Movement of tuberculosis patients and the failure to complete antituberculosis treatment","volume":"157","author":"Cummings","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"2024062808202669200_CIW376C142","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.2105\/AJPH.89.10.1581","article-title":"TB net tracking network provides continuity of care for mobile TB patients","volume":"89","author":"Harlow","year":"1999","journal-title":"Am J Public Health"},{"key":"2024062808202669200_CIW376C143","first-page":"1009","article-title":"Federal air travel restrictions for public health purposes\u2014United States, June 2007-May 2008","volume":"57","author":"Centers for Disease Control and Prevention","year":"2008","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2024062808202669200_CIW376C144","first-page":"570","article-title":"Public health interventions involving travelers with tuberculosis\u2014U.S. ports of entry, 2007\u20132012","volume":"61","author":"Centers for Disease Control and Prevention","year":"2012","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2024062808202669200_CIW376C145","article-title":"Guidance on ethics of tuberculosis prevention, care and control","author":"World Health Organization","year":"2010"},{"key":"2024062808202669200_CIW376C146","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES2014.19.9.20728","article-title":"Tuberculosis control in big cities and urban risk groups in the European Union: a consensus statement","volume":"19","author":"van Hest","year":"2014","journal-title":"Euro Surveill"},{"key":"2024062808202669200_CIW376C147","first-page":"7","article-title":"Updated guidelines for the use of nucleic acid amplification tests in the diagnosis of tuberculosis","volume":"58","author":"Centers for Disease Control and Prevention","year":"2009","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2024062808202669200_CIW376C148","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/S0140-6736(11)60438-8","article-title":"Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB\/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study","volume":"377","author":"Boehme","year":"2011","journal-title":"Lancet"},{"key":"2024062808202669200_CIW376C149","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1471-2180-5-55","article-title":"In-house nucleic acid amplification tests for the detection of Mycobacterium tuberculosis in sputum specimens: meta-analysis and meta-regression","volume":"5","author":"Flores","year":"2005","journal-title":"BMC Microbiol"},{"key":"2024062808202669200_CIW376C150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta11030","article-title":"A systematic review of rapid diagnostic tests for the detection of tuberculosis infection","volume":"11","author":"Dinnes","year":"2007","journal-title":"Health Technol Assess"},{"key":"2024062808202669200_CIW376C151","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1001\/jama.283.11.1445","article-title":"Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group","volume":"283","author":"Gordin","year":"2000","journal-title":"JAMA"},{"key":"2024062808202669200_CIW376C152","first-page":"1650","article-title":"Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection","volume":"60","author":"Centers for Disease Control and Prevention.","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2024062808202669200_CIW376C153","article-title":"Core curriculum on tuberculosis.","author":"Centers for Disease Control and Prevention","year":"2013","edition":"6th ed"},{"key":"2024062808202669200_CIW376C154","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1183\/13993003.01245-2015","article-title":"Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries","volume":"46","author":"Getahun","year":"2015","journal-title":"Eur Respir J"},{"issue":"4 pt 2","key":"2024062808202669200_CIW376C155","first-page":"S221","article-title":"Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement","volume":"161","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"2024062808202669200_CIW376C156","first-page":"555","article-title":"Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis","volume":"60","year":"1982","journal-title":"Bull World Health Organ"},{"key":"2024062808202669200_CIW376C157","first-page":"605","article-title":"Tuberculosis among patients with various radiologic abnormalities, followed by the chest clinic service","volume":"104","author":"Grzybowski","year":"1971","journal-title":"Am Rev Respir Dis"},{"key":"2024062808202669200_CIW376C158","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1080\/00039896.1972.10666182","article-title":"Preventive treatment of untreated, nonactive tuberculosis in an Eskimo population","volume":"25","author":"Comstock","year":"1972","journal-title":"Arch Environ Health"},{"key":"2024062808202669200_CIW376C159","first-page":"352","article-title":"Reactivations in inactive pulmonary tuberculosis","volume":"93","author":"Grzybows","year":"1966","journal-title":"Am Rev Respir Dis"},{"key":"2024062808202669200_CIW376C160","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1164\/rccm.200605-637OC","article-title":"Dosing schedules of 6-month regimens and relapse for pulmonary tuberculosis","volume":"174","author":"Chang","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"2024062808202669200_CIW376C161","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1097\/00002030-199910010-00012","article-title":"Relapse rates after short-course (6-month) treatment of tuberculosis in HIV-infected and uninfected persons","volume":"13","author":"Sterling","year":"1999","journal-title":"AIDS"},{"issue":"6 pt 1","key":"2024062808202669200_CIW376C162","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1164\/ajrccm.157.6.9707037","article-title":"Rifapentine and isoniazid in the continuation phase of treating pulmonary tuberculosis. Initial report","volume":"157","author":"Tam","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"2024062808202669200_CIW376C163","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1056\/NEJMoa1315817","article-title":"A four-month gatifloxacin-containing regimen for treating tuberculosis","volume":"371","author":"Merle","year":"2014","journal-title":"N Engl J Med"},{"key":"2024062808202669200_CIW376C164","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1314210","article-title":"High-dose rifapentine with moxifloxacin for pulmonary tuberculosis","volume":"371","author":"Jindani","year":"2014","journal-title":"N Engl J Med"},{"key":"2024062808202669200_CIW376C165","first-page":"6","article-title":"Operational research for improved tuberculosis control: the scope, the needs and the way forward","volume":"15","author":"Lienhardt","year":"2011","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024062808202669200_CIW376C166","doi-asserted-by":"crossref","first-page":"e1000443","DOI":"10.1371\/journal.pmed.1000443","article-title":"A multi-country non-inferiority cluster randomized trial of frontloaded smear microscopy for the diagnosis of pulmonary tuberculosis","volume":"8","author":"Cuevas","year":"2011","journal-title":"PLoS Med"},{"key":"2024062808202669200_CIW376C167","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1473-3099(12)70232-3","article-title":"Diagnostic accuracy of same-day microscopy versus standard microscopy for pulmonary tuberculosis: a systematic review and meta-analysis","volume":"13","author":"Davis","year":"2013","journal-title":"Lancet Infect Dis"},{"issue":"4 pt 1","key":"2024062808202669200_CIW376C168","first-page":"1376","article-title":"This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999","volume":"161","author":"Diagnostic Standards and Classification of Tuberculosis in Adults and Children","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"2024062808202669200_CIW376C169","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1164\/ajrccm\/143.2.262","article-title":"A controlled clinical comparison of 6 and 8 months of antituberculosis chemotherapy in the treatment of patients with silicotuberculosis in Hong Kong. Hong Kong Chest Service\/Tuberculosis Research Centre, Madras\/British Medical Research Council","volume":"143","year":"1991","journal-title":"Am Rev Respir Dis"},{"key":"2024062808202669200_CIW376C170","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1164\/rccm.200201-047OC","article-title":"A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment","volume":"165","author":"Bock","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"2024062808202669200_CIW376C171","article-title":"Clinical policies and protocols","author":"Bureau of Tuberculosis Control, New York City Department of Health and Mental Hygiene","year":"2008","edition":"4th ed"},{"key":"2024062808202669200_CIW376C172","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1128\/AAC.00345-10","article-title":"Effects of four different meal types on the population pharmacokinetics of single-dose rifapentine in healthy male volunteers","volume":"54","author":"Zvada","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2024062808202669200_CIW376C173","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1086\/520011","article-title":"Stability of antituberculosis drugs mixed in food","volume":"45","author":"Peloquin","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2024062808202669200_CIW376C174","first-page":"CD009913","article-title":"Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis","volume":"5","author":"Gallardo","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2024062808202669200_CIW376C175","doi-asserted-by":"crossref","first-page":"433","DOI":"10.5588\/ijtld.09.0439","article-title":"Evidence for promoting fixed-dose combination drugs in tuberculosis treatment and control: a review","volume":"15","author":"Monedero","year":"2011","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024062808202669200_CIW376C176","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1183\/09031936.00180612","article-title":"Fixed-dose combination antituberculosis therapy: a systematic review and meta-analysis","volume":"42","author":"Albanna","year":"2013","journal-title":"Eur Respir J"},{"key":"2024062808202669200_CIW376C177","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.5588\/ijtld.14.0281","article-title":"Results at 30 months of a randomised trial of FDCs and separate drugs for the treatment of tuberculosis","volume":"18","author":"Nunn","year":"2014","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024062808202669200_CIW376C178","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1001\/jama.2011.436","article-title":"Efficacy and safety of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis: the Study C randomized controlled trial","volume":"305","author":"Lienhardt","year":"2011","journal-title":"JAMA"},{"key":"2024062808202669200_CIW376C179","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2165\/00003088-199732020-00002","article-title":"The clinical pharmacokinetics of levofloxacin","volume":"32","author":"Fish","year":"1997","journal-title":"Clin Pharmacokinet"},{"key":"2024062808202669200_CIW376C180","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1586\/eri.12.13","article-title":"Cutaneous adverse drug reactions to anti-tuberculosis drugs: state of the art and into the future","volume":"10","author":"Lehloenya","year":"2012","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2024062808202669200_CIW376C181","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/S0962-8479(96)90056-8","article-title":"Rifampicin-induced immune thrombocytopenia","volume":"77","author":"Mehta","year":"1996","journal-title":"Tuber Lung Dis"},{"key":"2024062808202669200_CIW376C182","doi-asserted-by":"crossref","first-page":"76","DOI":"10.5588\/ijtld.12.0441","article-title":"Difficult clinical management of anti-tuberculosis DRESS syndrome","volume":"17","author":"Palmero","year":"2013","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024062808202669200_CIW376C183","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.tube.2011.05.007","article-title":"Clinical symptoms and microbiological outcomes in tuberculosis treatment trials","volume":"91","author":"Bark","year":"2011","journal-title":"Tuberculosis (Edinb)"},{"key":"2024062808202669200_CIW376C184","first-page":"20","article-title":"Fever response of patients on therapy for pulmonary tuberculosis","volume":"123","author":"Kiblawi","year":"1981","journal-title":"Am Rev Respir Dis"},{"key":"2024062808202669200_CIW376C185","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1378\/chest.114.3.933","article-title":"Paradoxical reactions in HIV and pulmonary TB","volume":"114","author":"Chien","year":"1998","journal-title":"Chest"},{"key":"2024062808202669200_CIW376C186","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ijid.2014.12.030","article-title":"Paradoxical reactions and immune reconstitution inflammatory syndrome in tuberculosis","volume":"32","author":"Bell","year":"2015","journal-title":"Int J Infect Dis"},{"key":"2024062808202669200_CIW376C187","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.ccm.2009.08.013","article-title":"Tuberculosis-associated immune reconstitution inflammatory syndrome and unmasking of tuberculosis by antiretroviral therapy","volume":"30","author":"Meintjes","year":"2009","journal-title":"Clin Chest Med"},{"key":"2024062808202669200_CIW376C188","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1378\/chest.99.2.465","article-title":"Toxic hepatitis with isoniazid and rifampin. A meta-analysis","volume":"99","author":"Steele","year":"1991","journal-title":"Chest"},{"key":"2024062808202669200_CIW376C189","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1440-1746.2007.05207.x","article-title":"Antituberculosis drug-induced hepatotoxicity: concise up-to-date review","volume":"23","author":"Tostmann","year":"2008","journal-title":"J Gastroenterol Hepatol"},{"key":"2024062808202669200_CIW376C190","doi-asserted-by":"crossref","first-page":"447","DOI":"10.5588\/ijtld.11.0766","article-title":"Incidence of ethambutol-related visual impairment during treatment of active tuberculosis","volume":"17","author":"Ezer","year":"2013","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024062808202669200_CIW376C191","first-page":"56","article-title":"Ocular toxicity of ethambutol","volume":"12","author":"Chan","year":"2006","journal-title":"Hong Kong Med J"},{"key":"2024062808202669200_CIW376C192","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10792-009-9293-z","article-title":"Risk factors for ethambutol optic toxicity","volume":"30","author":"Talbert Estlin","year":"2010","journal-title":"Int Ophthalmol"},{"key":"2024062808202669200_CIW376C193","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/S0140-6736(55)92696-9","article-title":"Optic neuritis following isoniazid therapy","volume":"269","author":"Keeping","year":"1955","journal-title":"Lancet"},{"key":"2024062808202669200_CIW376C194","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0009-9236(98)90036-4","article-title":"The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin","volume":"63","author":"Cato","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"2024062808202669200_CIW376C195","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1093\/infdis\/159.6.1115","article-title":"Evaluation of the antiviral effect of rifabutin in AIDS-related complex","volume":"159","author":"Torseth","year":"1989","journal-title":"J Infect Dis"},{"key":"2024062808202669200_CIW376C196","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1093\/clinids\/21.3.594","article-title":"Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease","volume":"21","author":"Griffith","year":"1995","journal-title":"Clin Infect Dis"},{"key":"2024062808202669200_CIW376C197","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1086\/496980","article-title":"Evaluation of the drug interaction between rifabutin and efavirenz in patients with HIV infection and tuberculosis","volume":"41","author":"Weiner","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2024062808202669200_CIW376C198","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1038\/clpt.1989.207","article-title":"Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin","volume":"46","author":"Nix","year":"1989","journal-title":"Clin Pharmacol Ther"},{"key":"2024062808202669200_CIW376C199","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1128\/AAC.36.4.830","article-title":"Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin","volume":"36","author":"Frost","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"2024062808202669200_CIW376C200","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1128\/AAC.33.11.1841","article-title":"Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers","volume":"33","author":"Polk","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"key":"2024062808202669200_CIW376C201","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1128\/AAC.38.2.248","article-title":"Effect of sucralfate on absorption of norfloxacin and ofloxacin","volume":"38","author":"Lehto","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"2024062808202669200_CIW376C202","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/clpt.1993.24","article-title":"Cations in the didanosine tablet reduce ciprofloxacin bioavailability","volume":"53","author":"Sahai","year":"1993","journal-title":"Clin Pharmacol Ther"},{"key":"2024062808202669200_CIW376C203","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1177\/106002809302701102","article-title":"Effect of multiple staggered doses of calcium on the bioavailability of ciprofloxacin","volume":"27","author":"Lomaestro","year":"1993","journal-title":"Ann Pharmacother"},{"key":"2024062808202669200_CIW376C204","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1086\/521894","article-title":"Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis","volume":"45","author":"Nijland","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2024062808202669200_CIW376C205","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.tube.2010.02.001","article-title":"Rifamycins\u2014obstacles and opportunities","volume":"90","author":"Aristoff","year":"2010","journal-title":"Tuberculosis (Edinb)"},{"key":"2024062808202669200_CIW376C206","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1185\/03007995.2012.747952","article-title":"Update on rifampin, rifabutin, and rifapentine drug interactions","volume":"29","author":"Baciewicz","year":"2013","journal-title":"Curr Med Res Opin"},{"key":"2024062808202669200_CIW376C207","doi-asserted-by":"crossref","first-page":"819","DOI":"10.2165\/00003088-200342090-00003","article-title":"Pharmacokinetic interactions with rifampicin: clinical relevance","volume":"42","author":"Niemi","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"2024062808202669200_CIW376C208","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1086\/313771","article-title":"Use of rifabutin with protease inhibitors for human immunodeficiency virus-infected patients with tuberculosis","volume":"30","author":"Narita","year":"2000","journal-title":"Clin Infect Dis"},{"key":"2024062808202669200_CIW376C209","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2165\/00003088-200140050-00002","article-title":"Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials","volume":"40","author":"Burman","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"2024062808202669200_CIW376C210","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection","volume":"365","author":"Sterling","year":"2011","journal-title":"N Engl J Med"},{"key":"2024062808202669200_CIW376C211","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1001\/archinte.162.9.985","article-title":"Rifampin and rifabutin drug interactions: an update","volume":"162","author":"Finch","year":"2002","journal-title":"Arch Intern Med"},{"key":"2024062808202669200_CIW376C212","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/j.1875-9114.1991.tb03603.x","article-title":"Rifampin and ansamycin interactions with cyclosporine after renal transplantation","volume":"11","author":"Vandevelde","year":"1991","journal-title":"Pharmacotherapy"},{"key":"2024062808202669200_CIW376C213","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1016\/S0272-6386(04)00947-3","article-title":"Treatment of tuberculosis with rifabutin in a renal transplant recipient","volume":"44","author":"Lopez-Montes","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"2024062808202669200_CIW376C214","doi-asserted-by":"crossref","first-page":"6","DOI":"10.5588\/ijtld.10.0626","article-title":"Protease inhibitor-containing antiretroviral treatment and tuberculosis: can rifabutin fill the breach?","volume":"16","author":"Loeliger","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024062808202669200_CIW376C215","article-title":"Managing drug interactions in the treatment of HIV-related tuberculosis","author":"Centers for Disease Control and Prevention","year":"2013"},{"key":"2024062808202669200_CIW376C216","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1093\/clinids\/18.2.266","article-title":"Coadministration of rifampin and itraconazole leads to undetectable levels of serum itraconazole","volume":"18","author":"Drayton","year":"1994","journal-title":"Clin Infect Dis"},{"key":"2024062808202669200_CIW376C217","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s002280050437","article-title":"Effect of rifampicin on the pharmacokinetics of itraconazole in normal volunteers and AIDS patients","volume":"54","author":"Jaruratanasirikul","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"2024062808202669200_CIW376C218","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1093\/jac\/21.5.633","article-title":"Pharmacokinetic study of the interaction between rifampicin and ketoconazole","volume":"21","author":"Doble","year":"1988","journal-title":"J Antimicrob Chemother"},{"key":"2024062808202669200_CIW376C219","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/00000441-199905000-00007","article-title":"Isoniazid drug and food interactions","volume":"317","author":"Self","year":"1999","journal-title":"Am J Med Sci"},{"key":"2024062808202669200_CIW376C220","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1128\/AAC.45.2.382-392.2001","article-title":"Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A","volume":"45","author":"Desta","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"2024062808202669200_CIW376C221","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1378\/chest.75.3.356","article-title":"Clinical importance of the interaction of phenytoin and isoniazid: a report from the Boston Collaborative Drug Surveillance Program","volume":"75","author":"Miller","year":"1979","journal-title":"Chest"},{"key":"2024062808202669200_CIW376C222","first-page":"377","article-title":"Diphenylhydantoin intoxication. A complication of isoniazid therapy","volume":"101","author":"Kutt","year":"1970","journal-title":"Am Rev Respir Dis"},{"key":"2024062808202669200_CIW376C223","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1542\/peds.69.4.494","article-title":"Carbamazepine-isoniazid interaction","volume":"69","author":"Block","year":"1982","journal-title":"Pediatrics"},{"key":"2024062808202669200_CIW376C224","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1056\/NEJM198211183072107","article-title":"Isoniazid-induced carbamazepine toxicity and vice versa: a double drug interaction","volume":"307","author":"Wright","year":"1982","journal-title":"N Engl J Med"},{"key":"2024062808202669200_CIW376C225","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/clpt.1981.94","article-title":"Diazepam interaction with antituberculosis drugs","volume":"29","author":"Ochs","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"2024062808202669200_CIW376C226","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/j.1365-2125.1983.tb02256.x","article-title":"Differential effect of isoniazid on triazolam oxidation and oxazepam conjugation","volume":"16","author":"Ochs","year":"1983","journal-title":"Br J Clin Pharmacol"},{"key":"2024062808202669200_CIW376C227","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2125.1985.tb05071.x","article-title":"Influence of rifampicin and isoniazid on the kinetics of phenytoin","volume":"20","author":"Kay","year":"1985","journal-title":"Br J Clin Pharmacol"},{"key":"2024062808202669200_CIW376C228","doi-asserted-by":"crossref","first-page":"799","DOI":"10.7326\/0003-4819-113-10-799","article-title":"Severe acetaminophen toxicity in a patient receiving isoniazid","volume":"113","author":"Murphy","year":"1990","journal-title":"Ann Intern Med"},{"key":"2024062808202669200_CIW376C229","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/BF00280078","article-title":"Interaction between isoniazid and valproate: a case of valproate overdosage","volume":"40","author":"Jonville","year":"1991","journal-title":"Eur J Clin Pharmacol"},{"key":"2024062808202669200_CIW376C230","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/00004850-199400920-00009","article-title":"Isoniazid and antidepressants: is there cause for concern?","volume":"9","author":"Judd","year":"1994","journal-title":"Int Clin Psychopharmacol"},{"key":"2024062808202669200_CIW376C231","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1001\/jama.1977.03280210069029","article-title":"Interaction of isoniazid and warfarin","volume":"238","author":"Rosenthal","year":"1977","journal-title":"JAMA"},{"key":"2024062808202669200_CIW376C232","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/106002808902300208","article-title":"Theophylline-isoniazid interaction","volume":"23","author":"Torrent","year":"1989","journal-title":"DICP"},{"key":"2024062808202669200_CIW376C233","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1176\/ajp.125.12.1725","article-title":"Possible interaction between disulfiram and isoniazid","volume":"125","author":"Whittington","year":"1969","journal-title":"Am J Psychiatry"},{"key":"2024062808202669200_CIW376C234","first-page":"839","article-title":"Lack of toxicity from concomitant directly observed disulfiram and isoniazid-containing therapy for active tuberculosis","volume":"6","author":"Burman","year":"2002","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024062808202669200_CIW376C235","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/j.1365-2125.1990.tb03669.x","article-title":"Comparative effects of ciprofloxacin and lomefloxacin on the oxidative metabolism of theophylline","volume":"29","author":"Robson","year":"1990","journal-title":"Br J Clin Pharmacol"},{"issue":"4A","key":"2024062808202669200_CIW376C236","first-page":"115","article-title":"Ciprofloxacin increases serum levels of theophylline","volume":"82","author":"Raoof","year":"1987","journal-title":"Am J Med"},{"key":"2024062808202669200_CIW376C237","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/j.1552-4604.1997.tb04362.x","article-title":"Absence of a pharmacokinetic interaction between intravenous theophylline and orally administered levofloxacin","volume":"37","author":"Gisclon","year":"1997","journal-title":"J Clin Pharmacol"},{"key":"2024062808202669200_CIW376C238","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s101560050026","article-title":"Influence of gatifloxacin, a new quinolone antibacterial, on pharmacokinetics of theophylline","volume":"5","author":"Niki","year":"1999","journal-title":"J Infect Chemother"},{"issue":"suppl 1","key":"2024062808202669200_CIW376C239","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2165\/00003088-200140001-00009","article-title":"Lack of pharmacokinetic interaction between moxifloxacin, a novel 8-methoxyfluoroquinolone, and theophylline","volume":"40","author":"Stass","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"2024062808202669200_CIW376C240","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1183\/09031936.00073213","article-title":"Therapeutic drug management: is it the future of multidrug-resistant tuberculosis treatment?","volume":"42","author":"Srivastava","year":"2013","journal-title":"Eur Respir J"},{"key":"2024062808202669200_CIW376C241","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1183\/09031936.00157914","article-title":"The role of therapeutic drug monitoring in individualised drug dosage and exposure measurement in tuberculosis and HIV co-infection","volume":"45","author":"Esposito","year":"2015","journal-title":"Eur Respir J"},{"key":"2024062808202669200_CIW376C242","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s40265-014-0222-8","article-title":"Therapeutic drug monitoring in the treatment of tuberculosis: an update","volume":"74","author":"Alsultan","year":"2014","journal-title":"Drugs"},{"key":"2024062808202669200_CIW376C243","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.tube.2011.02.004","article-title":"The pharmacokinetics and pharmacodynamics of rifampicin in adults and children in relation to the dosage recommended for children","volume":"91","author":"Donald","year":"2011","journal-title":"Tuberculosis (Edinb)"},{"key":"2024062808202669200_CIW376C244","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1093\/jac\/dkt524","article-title":"Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended doses","volume":"69","author":"Zvada","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2024062808202669200_CIW376C245","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1177\/106002809603000901","article-title":"Low antituberculosis drug concentrations in patients with AIDS","volume":"30","author":"Peloquin","year":"1996","journal-title":"Ann Pharmacother"},{"key":"2024062808202669200_CIW376C246","doi-asserted-by":"crossref","first-page":"289","DOI":"10.7326\/0003-4819-127-4-199708150-00006","article-title":"Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection","volume":"127","author":"Sahai","year":"1997","journal-title":"Ann Intern Med"},{"issue":"4 pt 1","key":"2024062808202669200_CIW376C247","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1164\/ajrccm.154.4.8887603","article-title":"Six-month supervised intermittent tuberculosis therapy in Haitian patients with and without HIV infection","volume":"154","author":"Chaisson","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"key":"2024062808202669200_CIW376C248","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1086\/520275","article-title":"Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG)","volume":"26","author":"el-Sadr","year":"1998","journal-title":"Clin Infect Dis"},{"key":"2024062808202669200_CIW376C249","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1086\/599040","article-title":"Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana","volume":"48","author":"Chideya","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2024062808202669200_CIW376C250","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1086\/606056","article-title":"Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis","volume":"49","author":"Boulanger","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2024062808202669200_CIW376C251","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1086\/598336","article-title":"Rifamycin-resistant Mycobacterium tuberculosis in the highly active antiretroviral therapy era: a report of 3 relapses with acquired rifampin resistance following alternate-day rifabutin and boosted protease inhibitor therapy","volume":"48","author":"Jenny-Avital","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2024062808202669200_CIW376C252","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1093\/infdis\/jit352","article-title":"Serum drug concentrations predictive of pulmonary tuberculosis outcomes","volume":"208","author":"Pasipanodya","year":"2013","journal-title":"J Infect Dis"},{"key":"2024062808202669200_CIW376C253","article-title":"WHO policy on collaborative TB\/HIV activities: guidelines for national programmes and other stakeholders","author":"World Health Organization","year":"2012"},{"issue":"RR-14","key":"2024062808202669200_CIW376C254","first-page":"1","article-title":"Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings","volume":"55","author":"Branson","year":"2006","journal-title":"MMWR Recomm Rep"},{"key":"2024062808202669200_CIW376C255","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1056\/NEJM199503233321204","article-title":"Pulmonary tuberculosis in HIV-infected patients in Zaire. A controlled trial of treatment for either 6 or 12 months","volume":"332","author":"Perriens","year":"1995","journal-title":"N Engl J Med"},{"key":"2024062808202669200_CIW376C256","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/clinids\/22.5.827","article-title":"Randomized controlled trial of a drug regimen that includes ciprofloxacin for the treatment of pulmonary tuberculosis","volume":"22","author":"Kennedy","year":"1996","journal-title":"Clin Infect Dis"},{"key":"2024062808202669200_CIW376C257","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1097\/00002030-199510000-00011","article-title":"Two-year follow-up of persons with HIV-1- and HIV-2-associated pulmonary tuberculosis treated with short-course chemotherapy in West Africa","volume":"9","author":"Kassim","year":"1995","journal-title":"AIDS"},{"key":"2024062808202669200_CIW376C258","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/S0140-6736(00)02870-1","article-title":"Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1-infected individuals: a randomised trial","volume":"356","author":"Fitzgerald","year":"2000","journal-title":"Lancet"},{"key":"2024062808202669200_CIW376C259","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S1473-3099(14)70733-9","article-title":"Early versus delayed initiation of highly active antiretroviral therapy for HIV-positive adults with newly diagnosed pulmonary tuberculosis (TB-HAART): a prospective, international, randomised, placebo-controlled trial","volume":"14","author":"Mfinanga","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"2024062808202669200_CIW376C260","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1056\/NEJMoa0905848","article-title":"Timing of initiation of antiretroviral drugs during tuberculosis therapy","volume":"362","author":"Abdool Karim","year":"2010","journal-title":"N Engl J Med"},{"key":"2024062808202669200_CIW376C261","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJMoa1013911","article-title":"Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis","volume":"365","author":"Blanc","year":"2011","journal-title":"N Engl J Med"},{"key":"2024062808202669200_CIW376C262","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1056\/NEJMoa1013607","article-title":"Timing of antiretroviral therapy for HIV-1 infection and tuberculosis","volume":"365","author":"Havlir","year":"2011","journal-title":"N Engl J Med"},{"key":"2024062808202669200_CIW376C263","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1056\/NEJMoa1014181","article-title":"Integration of antiretroviral therapy with tuberculosis treatment","volume":"365","author":"Abdool Karim","year":"2011","journal-title":"N Engl J Med"},{"key":"2024062808202669200_CIW376C264","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/QAI.0b013e31825b5e06","article-title":"Time to initiate antiretroviral therapy between 4 weeks and 12 weeks of tuberculosis treatment in HIV-infected patients: results from the TIME study","volume":"60","author":"Manosuthi","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2024062808202669200_CIW376C265","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1089\/aid.2009.0100","article-title":"Early versus delayed fixed dose combination abacavir\/lamivudine\/zidovudine in patients with HIV and tuberculosis in Tanzania","volume":"25","author":"Shao","year":"2009","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2024062808202669200_CIW376C266","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/1471-2334-12-168","article-title":"Early versus delayed initiation of antiretroviral therapy for Indian HIV-infected individuals with tuberculosis on antituberculosis treatment","volume":"12","author":"Sinha","year":"2012","journal-title":"BMC Infect Dis"},{"key":"2024062808202669200_CIW376C267","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1093\/cid\/cit246","article-title":"Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study","volume":"57","author":"Luetkemeyer","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2024062808202669200_CIW376C268","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/infdis\/jiu429","article-title":"Pharmacokinetics of efavirenz and treatment of HIV-1 among pregnant women with and without tuberculosis coinfection","volume":"211","author":"Dooley","year":"2015","journal-title":"J Infect Dis"},{"key":"2024062808202669200_CIW376C269","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ijid.2014.04.020","article-title":"Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a systematic review and meta-analysis","volume":"25","author":"Jiang","year":"2014","journal-title":"Int J Infect Dis"},{"key":"2024062808202669200_CIW376C270","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1093\/jac\/dkm484","article-title":"Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis","volume":"61","author":"Cohen","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"2024062808202669200_CIW376C271","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1177\/135965350701200406","article-title":"Nevirapine-based antiretroviral therapy started early in the course of tuberculosis treatment in adult Malawians","volume":"12","author":"van Oosterhout","year":"2007","journal-title":"Antivir Ther"},{"key":"2024062808202669200_CIW376C272","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1001\/jama.300.5.530","article-title":"Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy","volume":"300","author":"Boulle","year":"2008","journal-title":"JAMA"},{"key":"2024062808202669200_CIW376C273","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1177\/135965350801300414","article-title":"Pharmacokinetics and 48-week efficacy of nevirapine: 400 mg versus 600 mg per day in HIV-tuberculosis coinfection receiving rifampicin","volume":"13","author":"Avihingsanon","year":"2008","journal-title":"Antivir Ther"},{"key":"2024062808202669200_CIW376C274","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1473-3099(14)70711-X","article-title":"Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial","volume":"14","author":"Grinsztejn","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"2024062808202669200_CIW376C275","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/QAI.0b013e318276cda9","article-title":"Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects","volume":"62","author":"Dooley","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2024062808202669200_CIW376C276","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1128\/AAC.01468-08","article-title":"Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir","volume":"53","author":"Wenning","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2024062808202669200_CIW376C277","first-page":"1290","article-title":"Paradoxical response during anti-tuberculosis treatment in HIV-negative patients with pulmonary tuberculosis","volume":"11","author":"Cheng","year":"2007","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024062808202669200_CIW376C278","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1093\/cid\/cir230","article-title":"Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)\u2014associated tuberculous meningitis","volume":"52","author":"Torok","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2024062808202669200_CIW376C279","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMra1008049","article-title":"Tuberculosis in children","volume":"367","author":"Perez-Velez","year":"2012","journal-title":"N Engl J Med"},{"key":"2024062808202669200_CIW376C280","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s00247-012-2399-x","article-title":"CT features of lymphobronchial tuberculosis in children, including complications and associated abnormalities","volume":"42","author":"Lucas","year":"2012","journal-title":"Pediatr Radiol"},{"issue":"suppl 3","key":"2024062808202669200_CIW376C281","doi-asserted-by":"crossref","first-page":"S179","DOI":"10.1093\/cid\/civ581","article-title":"Clinical case definitions for classification of intrathoracic tuberculosis in children: an update","volume":"61","author":"Graham","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2024062808202669200_CIW376C282","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S0140-6736(05)17702-2","article-title":"Induced sputum versus gastric lavage for microbiological confirmation of pulmonary tuberculosis in infants and young children: a prospective study","volume":"365","author":"Zar","year":"2005","journal-title":"Lancet"},{"key":"2024062808202669200_CIW376C283","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0962-8479(05)80027-9","article-title":"Value of bronchoalveolar lavage and gastric lavage in the diagnosis of pulmonary tuberculosis in children","volume":"76","author":"Somu","year":"1995","journal-title":"Tuber Lung Dis"},{"key":"2024062808202669200_CIW376C284","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.tube.2010.07.003","article-title":"The chemotherapy of tuberculous meningitis in children and adults","volume":"90","author":"Donald","year":"2010","journal-title":"Tuberculosis (Edinb)"},{"key":"2024062808202669200_CIW376C285","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/MOP.0b013e32835357c3","article-title":"Pediatric tuberculosis: new guidelines and recommendations","volume":"24","author":"Perez-Velez","year":"2012","journal-title":"Curr Opin Pediatr"},{"key":"2024062808202669200_CIW376C286","article-title":"Rapid advice: treatment of tuberculosis in children","author":"World Health Organization","year":"2010"},{"key":"2024062808202669200_CIW376C287","article-title":"Guidance for national tuberculosis programmes on the management of tuberculosis in children","author":"World Health Organization","year":"2014","edition":"2nd ed"},{"key":"2024062808202669200_CIW376C288","doi-asserted-by":"crossref","first-page":"722","DOI":"10.5588\/ijtld.10.0284","article-title":"Polyneuropathy, anti-tuberculosis treatment and the role of pyridoxine in the HIV\/AIDS era: a systematic review","volume":"15","author":"van der Watt","year":"2011","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024062808202669200_CIW376C289","volume-title":"The Harriet Lane Handbook: a manual for pediatric house officers","author":"Engorn","year":"2015","edition":"20th ed"},{"issue":"suppl 1","key":"2024062808202669200_CIW376C290","doi-asserted-by":"crossref","first-page":"3","DOI":"10.5588\/ijtld.15.0416","article-title":"The background and rationale for a new fixed-dose combination for first-line treatment of tuberculosis in children","volume":"19","author":"Graham","year":"2015","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024062808202669200_CIW376C291","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1128\/AAC.00064-11","article-title":"Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis","volume":"55","author":"Thwaites","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2024062808202669200_CIW376C292","year":"2016"},{"key":"2024062808202669200_CIW376C293","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0041-3879(79)90042-4","article-title":"Lymph node tuberculosis: a comparison of treatments 18 months after completion of chemotherapy","volume":"60","author":"Campbell","year":"1979","journal-title":"Tubercle"},{"key":"2024062808202669200_CIW376C294","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1136\/bmj.290.6475.1106","article-title":"Short course chemotherapy for tuberculosis of lymph nodes: a controlled trial. British Thoracic Society Research Committee","volume":"290","year":"1985","journal-title":"Br Med J (Clin Res Ed)"},{"key":"2024062808202669200_CIW376C295","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1136\/bmj.301.6748.359","article-title":"Short course chemotherapy for tuberculous lymphadenitis in children","volume":"301","author":"Jawahar","year":"1990","journal-title":"BMJ"},{"key":"2024062808202669200_CIW376C296","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0954-6111(06)80142-3","article-title":"Six-months versus nine-months chemotherapy for tuberculosis of lymph nodes: preliminary results. British Thoracic Society Research Committee","volume":"86","year":"1992","journal-title":"Respir Med"},{"key":"2024062808202669200_CIW376C297","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0954-6111(05)80265-3","article-title":"Six months versus nine months chemotherapy for tuberculosis of lymph nodes: final results","volume":"87","author":"Campbell","year":"1993","journal-title":"Respir Med"},{"key":"2024062808202669200_CIW376C298","first-page":"189","article-title":"Prospective randomized study of thrice weekly six-month and nine-month chemotherapy for cervical tuberculous lymphadenopathy","volume":"116","author":"Yuen","year":"1997","journal-title":"Otolaryngol Head Neck Surg"},{"key":"2024062808202669200_CIW376C299","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0041-3879(77)90041-1","article-title":"Lymph node tuberculosis: a comparison of various methods of treatment","volume":"58","author":"Campbell","year":"1977","journal-title":"Tubercle"},{"key":"2024062808202669200_CIW376C300","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1001\/archotol.129.3.341","article-title":"Management of nontuberculous mycobacterial cervical lymphadenitis","volume":"129","author":"Mandell","year":"2003","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"2024062808202669200_CIW376C301","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1093\/clinids\/20.4.954","article-title":"Mycobacterial lymphadenitis in children: a prospective study of 105 nontuberculous cases with long-term follow-up","volume":"20","author":"Wolinsky","year":"1995","journal-title":"Clin Infect Dis"},{"key":"2024062808202669200_CIW376C302","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/0041-3879(86)90014-0","article-title":"A controlled trial of six-month and nine-month regimens of chemotherapy in patients undergoing radical surgery for tuberculosis of the spine in Hong Kong. Tenth report of the Medical Research Council Working Party on Tuberculosis of the Spine","volume":"67","year":"1986","journal-title":"Tubercle"},{"key":"2024062808202669200_CIW376C303","first-page":"240","article-title":"Controlled trial of short-course regimens of chemotherapy in the ambulatory treatment of spinal tuberculosis. Results at three years of a study in Korea. Twelfth report of the Medical Research Council Working Party on Tuberculosis of the Spine","volume":"75","year":"1993","journal-title":". J Bone Joint Surg Br"},{"key":"2024062808202669200_CIW376C304","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s002640050311","article-title":"Five-year assessment of controlled trials of short-course chemotherapy regimens of 6, 9 or 18 months' duration for spinal tuberculosis in patients ambulatory from the start or undergoing radical surgery. Fourteenth report of the Medical Research Council Working Party on Tuberculosis of the Spine","volume":"23","year":"1999","journal-title":"Int Orthop"},{"key":"2024062808202669200_CIW376C305","first-page":"77","article-title":"Pott's paraplegia: an account of the treatment of 89 consecutive patients","volume":"24","author":"Pattisson","year":"1986","journal-title":"Paraplegia"},{"key":"2024062808202669200_CIW376C306","first-page":"CD004532","article-title":"Routine surgery in addition to chemotherapy for treating spinal tuberculosis","author":"Jutte","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"2024062808202669200_CIW376C307","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.spinee.2004.05.255","article-title":"Results of nonsurgical treatment of thoracic spinal tuberculosis in adults","volume":"5","author":"Nene","year":"2005","journal-title":"Spine J"},{"key":"2024062808202669200_CIW376C308","first-page":"CD001876","article-title":"Corticosteroids for tuberculous pleurisy","author":"Engel","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"2024062808202669200_CIW376C309","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1378\/chest.94.6.1256","article-title":"Corticosteroids in the treatment of tuberculous pleurisy. A double-blind, placebo-controlled, randomized study","volume":"94","author":"Lee","year":"1988","journal-title":"Chest"},{"key":"2024062808202669200_CIW376C310","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1136\/thx.50.12.1305","article-title":"Randomised trial of corticosteroids in the treatment of tuberculous pleurisy","volume":"50","author":"Galarza","year":"1995","journal-title":"Thorax"},{"key":"2024062808202669200_CIW376C311","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1378\/chest.110.2.333","article-title":"Corticosteroids in the treatment of tuberculous pleurisy. A double-blind, placebo-controlled, randomized study","volume":"110","author":"Wyser","year":"1996","journal-title":"Chest"},{"key":"2024062808202669200_CIW376C312","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1086\/422257","article-title":"A randomized, double-blind, placebo-controlled trial of the use of prednisolone as an adjunct to treatment in HIV-1-associated pleural tuberculosis","volume":"190","author":"Elliott","year":"2004","journal-title":"J Infect Dis"},{"key":"2024062808202669200_CIW376C313","first-page":"82","article-title":"Tuberculous empyema","volume":"14","author":"Sahn","year":"1999","journal-title":"Semin Respir Infect"},{"key":"2024062808202669200_CIW376C314","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S1473-3099(14)70852-7","article-title":"Treatment outcomes of childhood tuberculous meningitis: a systematic review and meta-analysis","volume":"14","author":"Chiang","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"2024062808202669200_CIW376C315","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/0002-9343(92)90579-Z","article-title":"Tuberculous meningitis in patients with and without human immunodeficiency virus infection","volume":"93","author":"Dube","year":"1992","journal-title":"Am J Med"},{"key":"2024062808202669200_CIW376C316","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1056\/NEJM199203053261004","article-title":"Tuberculous meningitis in patients infected with the human immunodeficiency virus","volume":"326","author":"Berenguer","year":"1992","journal-title":"N Engl J Med"},{"key":"2024062808202669200_CIW376C317","first-page":"325","article-title":"Tuberculous meningitis at a large inner-city medical center","volume":"313","author":"Porkert","year":"1997","journal-title":"Am J Med Sci"},{"key":"2024062808202669200_CIW376C318","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1086\/498220","article-title":"The influence of HIV infection on clinical presentation, response to treatment, and outcome in adults with Tuberculous meningitis","volume":"192","author":"Thwaites","year":"2005","journal-title":"J Infect Dis"},{"key":"2024062808202669200_CIW376C319","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1473-3099(12)70264-5","article-title":"Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial","volume":"13","author":"Ruslami","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"2024062808202669200_CIW376C320","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1745-6215-12-25","article-title":"Intensified treatment with high dose rifampicin and levofloxacin compared to standard treatment for adult patients with tuberculous meningitis (TBM-IT): protocol for a randomized controlled trial","volume":"12","author":"Heemskerk","year":"2011","journal-title":"Trials"},{"key":"2024062808202669200_CIW376C321","doi-asserted-by":"crossref","first-page":"609","DOI":"10.7326\/0003-4819-85-5-609","article-title":"Miliary tuberculosis and adult respiratory distress syndrome","volume":"85","author":"Huseby","year":"1976","journal-title":"Ann Intern Med"},{"key":"2024062808202669200_CIW376C322","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1378\/chest.73.1.37","article-title":"The adult respiratory distress syndrome associated with miliary tuberculosis","volume":"73","author":"Murray","year":"1978","journal-title":"Chest"},{"key":"2024062808202669200_CIW376C323","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.2169\/internalmedicine.48.1974","article-title":"Addison's disease induced by miliary tuberculosis and the administration of rifampicin","volume":"48","author":"Yokoyama","year":"2009","journal-title":"Intern Med"},{"key":"2024062808202669200_CIW376C324","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S1473-3099(05)70163-8","article-title":"Miliary tuberculosis: new insights into an old disease","volume":"5","author":"Sharma","year":"2005","journal-title":"Lancet Infect Dis"},{"key":"2024062808202669200_CIW376C325","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.clineuro.2009.11.013","article-title":"Neurological complications of miliary tuberculosis","volume":"112","author":"Garg","year":"2010","journal-title":"Clin Neurol Neurosurg"},{"key":"2024062808202669200_CIW376C326","first-page":"50","article-title":"Genito-urinary tuberculosis. A study of the disease in one unit over a period of 24 years","volume":"49","author":"Gow","year":"1971","journal-title":"Ann R Coll Surg Engl"},{"key":"2024062808202669200_CIW376C327","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/00005792-197409000-00004","article-title":"Genitourinary tuberculosis: review of 102 cases","volume":"53","author":"Christensen","year":"1974","journal-title":"Medicine (Baltimore)"},{"key":"2024062808202669200_CIW376C328","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/0002-9343(77)90279-0","article-title":"Genitourinary tuberculosis. Clinical features in a general hospital population","volume":"63","author":"Simon","year":"1977","journal-title":"Am J Med"},{"key":"2024062808202669200_CIW376C329","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1159\/000472484","article-title":"Six-month chemotherapy for urogenital tuberculosis","volume":"11","author":"Skutil","year":"1985","journal-title":"Eur Urol"},{"key":"2024062808202669200_CIW376C330","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/PL00012277","article-title":"Indications for surgical management of genitourinary tuberculosis","volume":"21","author":"Carl","year":"1997","journal-title":"World J Surg"},{"key":"2024062808202669200_CIW376C331","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/nrurol.2011.172","article-title":"Etiology and management of genitourinary tuberculosis","volume":"8","author":"Abbara","year":"2011","journal-title":"Nat Rev Urol"},{"key":"2024062808202669200_CIW376C332","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1097\/MCP.0b013e328337f23a","article-title":"Urine for the diagnosis of tuberculosis: current approaches, clinical applicability, and new developments","volume":"16","author":"Peter","year":"2010","journal-title":"Curr Opin Pulm Med"},{"key":"2024062808202669200_CIW376C333","first-page":"549","article-title":"Tuberculous peritonitis\u2014report of 30 cases and review of the literature","volume":"56","author":"Bastani","year":"1985","journal-title":"Q J Med"},{"key":"2024062808202669200_CIW376C334","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1097\/00042737-200105000-00019","article-title":"Tuberculous peritonitis\u2014reports of 26 cases, detailing diagnostic and therapeutic problems","volume":"13","author":"Demir","year":"2001","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2024062808202669200_CIW376C335","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1097\/00042737-200509000-00013","article-title":"Abdominal tuberculosis in Bradford, UK: 1992\u20132002","volume":"17","author":"Singhal","year":"2005","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2024062808202669200_CIW376C336","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/qjmed\/hct003","article-title":"Abdominal tuberculosis: a retrospective review of cases presenting to a UK district hospital","volume":"106","author":"Mamo","year":"2013","journal-title":"QJM"},{"key":"2024062808202669200_CIW376C337","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/j.1463-1318.2007.01337.x","article-title":"Intra-abdominal and gastrointestinal tuberculosis","volume":"9","author":"Rasheed","year":"2007","journal-title":"Colorectal Dis"},{"key":"2024062808202669200_CIW376C338","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1086\/514627","article-title":"Corticosteroid treatment of peritoneal tuberculosis","volume":"27","author":"Alrajhi","year":"1998","journal-title":"Clin Infect Dis"},{"key":"2024062808202669200_CIW376C339","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1164\/ajrccm\/139.4.871","article-title":"A controlled trial of 3-month, 4-month, and 6-month regimens of chemotherapy for sputum-smear-negative pulmonary tuberculosis. Results at 5 years. Hong Kong Chest Service\/Tuberculosis Research Centre, Madras\/British Medical Research Council","volume":"139","year":"1989","journal-title":"Am Rev Respir Dis"},{"key":"2024062808202669200_CIW376C340","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1164\/ajrccm\/139.4.867","article-title":"Smear- and culture-negative pulmonary tuberculosis: four-month short-course chemotherapy","volume":"139","author":"Dutt","year":"1989","journal-title":"Am Rev Respir Dis"},{"key":"2024062808202669200_CIW376C341","doi-asserted-by":"crossref","first-page":"175","DOI":"10.47102\/annals-acadmedsg.V31N2p175","article-title":"Four-month chemotherapy in the treatment of smear-negative pulmonary tuberculosis: results at 30 to 60 months","volume":"31","author":"Teo","year":"2002","journal-title":"Ann Acad Med Singapore"},{"key":"2024062808202669200_CIW376C342","first-page":"65","article-title":"Treatment of tuberculosis during pregnancy","volume":"122","author":"Snider","year":"1980","journal-title":"Am Rev Respir Dis"},{"key":"2024062808202669200_CIW376C343","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0020-7292(94)90064-7","article-title":"Perinatal outcome in pregnancies complicated by pulmonary tuberculosis","volume":"44","author":"Jana","year":"1994","journal-title":"Int J Gynaecol Obstet"},{"key":"2024062808202669200_CIW376C344","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0140-6736(95)91263-0","article-title":"Managing tuberculosis during pregnancy","volume":"346","author":"Davidson","year":"1995","journal-title":"Lancet"},{"key":"2024062808202669200_CIW376C345","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1055\/s-2007-993948","article-title":"Pregnancy and tuberculosis: influence of treatment on perinatal outcome","volume":"15","author":"Figueroa-Damian","year":"1998","journal-title":"Am J Perinatol"},{"key":"2024062808202669200_CIW376C346","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1136\/thorax.55.2.129","article-title":"Tuberculosis diagnosed during pregnancy: a prospective study from London","volume":"55","author":"Llewelyn","year":"2000","journal-title":"Thorax"},{"key":"2024062808202669200_CIW376C347","first-page":"564","article-title":"A population-based case-control study of the safety of oral anti-tuberculosis drug treatment during pregnancy","volume":"5","author":"Czeizel","year":"2001","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024062808202669200_CIW376C348","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1186\/s12879-014-0617-x","article-title":"Tuberculosis care for pregnant women: a systematic review","volume":"14","author":"Nguyen","year":"2014","journal-title":"BMC Infect Dis"},{"key":"2024062808202669200_CIW376C349","volume-title":"Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk","author":"Briggs","year":"2015","edition":"10th ed"},{"key":"2024062808202669200_CIW376C350","article-title":"Pregnancy, lactation, and reproductive potential: labeling for human prescription drug and biological products, content and format. Draft guidance for industry","author":"US Food and Drug Administration"},{"key":"2024062808202669200_CIW376C351","doi-asserted-by":"crossref","first-page":"547","DOI":"10.5588\/ijtld.10.0140","article-title":"Standardised second-line treatment of multidrug-resistant tuberculosis during pregnancy","volume":"15","author":"Tabarsi","year":"2011","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024062808202669200_CIW376C352","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1086\/598191","article-title":"Drug-resistant tuberculosis and pregnancy: treatment outcomes of 38 cases in Lima, Peru","volume":"48","author":"Palacios","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2024062808202669200_CIW376C353","first-page":"706","article-title":"Pregnancies complicated by multidrug-resistant tuberculosis and HIV co-infection in Durban, South Africa","volume":"11","author":"Khan","year":"2007","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024062808202669200_CIW376C354","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1086\/374225","article-title":"Treatment of multidrug-resistant tuberculosis during pregnancy: a report of 7 cases","volume":"36","author":"Shin","year":"2003","journal-title":"Clin Infect Dis"},{"key":"2024062808202669200_CIW376C355","doi-asserted-by":"crossref","first-page":"e710","DOI":"10.1016\/S2214-109X(14)70330-4","article-title":"Tuberculosis in pregnancy: an estimate of the global burden of disease","volume":"2","author":"Sugarman","year":"2014","journal-title":"Lancet Glob Health"},{"key":"2024062808202669200_CIW376C356","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1093\/cid\/cis732","article-title":"Tuberculosis in pregnant and postpartum women: epidemiology, management, and research gaps","volume":"55","author":"Mathad","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2024062808202669200_CIW376C357","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1001\/jama.1954.02950170003002","article-title":"Effects of isoniazid on pyridoxine metabolism","volume":"156","author":"Biehl","year":"1954","journal-title":"J Am Med Assoc"},{"key":"2024062808202669200_CIW376C358","first-page":"714","article-title":"Maternal plasma concentration of pyridoxal phosphate during pregnancy: adequacy of vitamin B6 supplementation during isoniazid therapy","volume":"126","author":"Atkins","year":"1982","journal-title":"Am Rev Respir Dis"},{"key":"2024062808202669200_CIW376C359","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/nri3523","article-title":"The immune system and kidney disease: basic concepts and clinical implications","volume":"13","author":"Kurts","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"2024062808202669200_CIW376C360","doi-asserted-by":"crossref","first-page":"352","DOI":"10.5588\/ijtld.13.0726","article-title":"Impact of chronic renal failure on anti-tuberculosis treatment outcomes","volume":"18","author":"Baghaei","year":"2014","journal-title":"Int J Tuberc Lung Dis"},{"issue":"5 pt 1","key":"2024062808202669200_CIW376C361","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1164\/ajrccm.159.5.9810034","article-title":"The effect of hemodialysis on isoniazid, rifampin, pyrazinamide, and ethambutol","volume":"159","author":"Malone","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"2024062808202669200_CIW376C362","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1378\/chest.116.4.984","article-title":"The effect of hemodialysis on cycloserine, ethionamide, para-aminosalicylate, and clofazimine","volume":"116","author":"Malone","year":"1999","journal-title":"Chest"},{"key":"2024062808202669200_CIW376C363","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2165\/00003088-200544030-00001","article-title":"Pharmacokinetic considerations in the treatment of tuberculosis in patients with renal failure","volume":"44","author":"Launay-Vacher","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"2024062808202669200_CIW376C364","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S0929-6646(09)60040-1","article-title":"A prospective study of hepatitis during antituberculous treatment in Taiwanese patients and a review of the literature","volume":"108","author":"Sun","year":"2009","journal-title":"J Formos Med Assoc"},{"key":"2024062808202669200_CIW376C365","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1086\/514993","article-title":"Mycobacterium tuberculosis infection in solid-organ transplant recipients: impact and implications for management","volume":"27","author":"Singh","year":"1998","journal-title":"Clin Infect Dis"},{"key":"2024062808202669200_CIW376C366","first-page":"616","article-title":"Hepatitis C virus infection increases hepatitis risk during anti-tuberculosis treatment","volume":"14","author":"Chien","year":"2010","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024062808202669200_CIW376C367","doi-asserted-by":"crossref","first-page":"e83892","DOI":"10.1371\/journal.pone.0083892","article-title":"Hepatitis C virus co-infection increases the risk of anti-tuberculosis drug-induced hepatotoxicity among patients with pulmonary tuberculosis","volume":"8","author":"Lomtadze","year":"2013","journal-title":"PLoS One"},{"key":"2024062808202669200_CIW376C368","first-page":"699","article-title":"Hepatotoxicity of tuberculosis chemotherapy under general programme conditions in Singapore","volume":"6","author":"Teleman","year":"2002","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024062808202669200_CIW376C369","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/S0168-8278(99)80325-0","article-title":"Antecedent liver disease and drug toxicity","volume":"31","author":"Schenker","year":"1999","journal-title":"J Hepatol"},{"key":"2024062808202669200_CIW376C370","doi-asserted-by":"crossref","first-page":"397","DOI":"10.7326\/0003-4819-76-3-112-6-397","article-title":"USPHS Tuberculosis Short-Course Chemotherapy Trial 21: effectiveness, toxicity, and acceptability. The report of final results","volume":"112","author":"Combs","year":"1990","journal-title":"Ann Intern Med"},{"key":"2024062808202669200_CIW376C371","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/0007-0971(84)90165-7","article-title":"A controlled trial of 6 months' chemotherapy in pulmonary tuberculosis. Final report: results during the 36 months after the end of chemotherapy and beyond. British Thoracic Society","volume":"78","year":"1984","journal-title":"Br J Dis Chest"},{"key":"2024062808202669200_CIW376C372","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0041-3879(88)90047-5","article-title":"Comparison of a daily and three intermittent retreatment regimens for pulmonary tuberculosis administered under programme conditions","volume":"69","author":"Hong","year":"1988","journal-title":"Tubercle"},{"key":"2024062808202669200_CIW376C373","first-page":"423","article-title":"Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis","volume":"133","author":"Mitchison","year":"1986","journal-title":"Am Rev Respir Dis"},{"key":"2024062808202669200_CIW376C374","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1093\/cid\/cis1008","article-title":"Aggressive regimens for multidrug-resistant tuberculosis reduce recurrence","volume":"56","author":"Franke","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2024062808202669200_CIW376C375","doi-asserted-by":"crossref","first-page":"5760","DOI":"10.3748\/wjg.v20.i19.5760","article-title":"Antitubercular therapy in patients with cirrhosis: challenges and options","volume":"20","author":"Kumar","year":"2014","journal-title":"World J Gastroenterol"},{"key":"2024062808202669200_CIW376C376","doi-asserted-by":"crossref","first-page":"394","DOI":"10.2165\/00002018-199615060-00004","article-title":"Hepatotoxicity of antitubercular treatments. Rationale for monitoring liver status","volume":"15","author":"Durand","year":"1996","journal-title":"Drug Saf"},{"key":"2024062808202669200_CIW376C377","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1093\/clinchem\/46.12.2027","article-title":"Diagnosis and monitoring of hepatic injury. I. Performance characteristics of laboratory tests","volume":"46","author":"Dufour","year":"2000","journal-title":"Clin Chem"},{"key":"2024062808202669200_CIW376C378","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1164\/rccm.200206-626OC","article-title":"Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis","volume":"167","author":"Yee","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"2024062808202669200_CIW376C379","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1164\/rccm.200802-355OC","article-title":"Hepatotoxicity of pyrazinamide: cohort and case-control analyses","volume":"177","author":"Chang","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"2024062808202669200_CIW376C380","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3899\/jrheum.140106","article-title":"Restarting biologics and management of patients with flares of inflammatory rheumatic disorders or psoriasis during active tuberculosis treatment","volume":"91","author":"Cantini","year":"2014","journal-title":"J Rheumatol Suppl"},{"key":"2024062808202669200_CIW376C381","first-page":"341","article-title":"Tuberculosis in California dialysis patients","volume":"8","author":"Ahmed","year":"2004","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024062808202669200_CIW376C382","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1136\/thoraxjnl-2012-201756","article-title":"Association of diabetes and tuberculosis: impact on treatment and post-treatment outcomes","volume":"68","author":"Jimenez-Corona","year":"2013","journal-title":"Thorax"},{"key":"2024062808202669200_CIW376C383","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s11892-014-0505-1","article-title":"Is there an effect of glucose lowering treatment on incidence and prognosis of tuberculosis? A systematic review","volume":"14","author":"Jorgensen","year":"2014","journal-title":"Curr Diab Rep"},{"key":"2024062808202669200_CIW376C384","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1164\/ajrccm\/136.4.808","article-title":"Short-course chemotherapy of pulmonary tuberculosis in pneumoconiotic patients","volume":"136","author":"Lin","year":"1987","journal-title":"Am Rev Respir Dis"},{"key":"2024062808202669200_CIW376C385","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1097\/00007890-199705150-00015","article-title":"Clinical presentation and outcome of tuberculosis in kidney, liver, and heart transplant recipients in Spain. Spanish Transplantation Infection Study Group, GESITRA","volume":"63","author":"Aguado","year":"1997","journal-title":"Transplantation"},{"key":"2024062808202669200_CIW376C386","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1093\/rheumatology\/keu041","article-title":"Safety of resuming tumour necrosis factor inhibitors in patients who developed tuberculosis as a complication of previous TNF inhibitors","volume":"53","author":"Kim","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"2024062808202669200_CIW376C387","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3346\/jkms.2014.29.1.38","article-title":"Safe re-administration of tumor necrosis factor-alpha (TNFalpha) inhibitors in patients with rheumatoid arthritis or ankylosing spondylitis who developed active tuberculosis on previous anti-TNFalpha therapy","volume":"29","author":"Suh","year":"2014","journal-title":"J Korean Med Sci"},{"key":"2024062808202669200_CIW376C388","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jbspin.2015.04.022","article-title":"Paradoxical anti-TNF-associated TB worsening: frequency and factors associated with IRIS","volume":"83","author":"Rivoisy","year":"2016","journal-title":"Joint Bone Spine"},{"key":"2024062808202669200_CIW376C389","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1086\/597590","article-title":"Tuberculosis in solid-organ transplant recipients: consensus statement of the group for the study of infection in transplant recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology","volume":"48","author":"Aguado","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2024062808202669200_CIW376C390","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1056\/NEJM199304223281601","article-title":"Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection","volume":"328","author":"Small","year":"1993","journal-title":"N Engl J Med"},{"key":"2024062808202669200_CIW376C391","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1056\/NEJM199910143411602","article-title":"Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment","volume":"341","author":"van Rie","year":"1999","journal-title":"N Engl J Med"},{"key":"2024062808202669200_CIW376C392","first-page":"3","article-title":"Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Final report at 5 years: prognostic value of various measures","volume":"6","author":"Tam","year":"2002","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024062808202669200_CIW376C393","first-page":"241","article-title":"Timing of relapse in short-course chemotherapy trials for tuberculosis","volume":"14","author":"Nunn","year":"2010","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024062808202669200_CIW376C394","first-page":"796","article-title":"Role of individual drugs in the chemotherapy of tuberculosis","volume":"4","author":"Mitchison","year":"2000","journal-title":"Int J Tuberc Lung Dis"},{"issue":"4 pt 1","key":"2024062808202669200_CIW376C395","first-page":"700","article-title":"Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 months. Hong Kong Chest Service\/British Medical Research Council","volume":"143","year":"1991","journal-title":"Am Rev Respir Dis"},{"key":"2024062808202669200_CIW376C396","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1016\/S0140-6736(02)08830-X","article-title":"Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru","volume":"359","author":"Suarez","year":"2002","journal-title":"Lancet"},{"key":"2024062808202669200_CIW376C397","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJM199404283301702","article-title":"The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis","volume":"330","author":"Weis","year":"1994","journal-title":"N Engl J Med"},{"key":"2024062808202669200_CIW376C398","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/S0140-6736(04)17141-9","article-title":"Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial","volume":"364","author":"Jindani","year":"2004","journal-title":"Lancet"},{"key":"2024062808202669200_CIW376C399","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1378\/chest.111.5.1162","article-title":"Retreatment tuberculosis cases. Factors associated with drug resistance and adverse outcomes","volume":"111","author":"Kritski","year":"1997","journal-title":"Chest"},{"key":"2024062808202669200_CIW376C400","first-page":"129","article-title":"Low failure rate in standardised retreatment of tuberculosis in Nicaragua: patient category, drug resistance and survival of \u2018chronic\u2019 patients","volume":"5","author":"Heldal","year":"2001","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024062808202669200_CIW376C401","first-page":"52","article-title":"Identifying early treatment failure on category I therapy for pulmonary tuberculosis in Lima Ciudad, Peru","volume":"8","author":"Chavez Pachas","year":"2004","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024062808202669200_CIW376C402","first-page":"31","article-title":"Development of acquired drug resistance in recurrent tuberculosis patients with various previous treatment outcomes","volume":"8","author":"Yoshiyama","year":"2004","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024062808202669200_CIW376C403","doi-asserted-by":"crossref","first-page":"876","DOI":"10.5588\/ijtld.13.0853","article-title":"False-positive Xpert(R) MTB\/RIF assays in previously treated patients: need for caution in interpreting results","volume":"18","author":"Boyles","year":"2014","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024062808202669200_CIW376C404","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1183\/09031936.00073611","article-title":"WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update","volume":"38","author":"Falzon","year":"2011","journal-title":"Eur Respir J"},{"key":"2024062808202669200_CIW376C405","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1001\/jama.1996.03530300036037","article-title":"Origin and interstate spread of a New York City multidrug-resistant Mycobacterium tuberculosis clone family","volume":"275","author":"Bifani","year":"1996","journal-title":"JAMA"},{"key":"2024062808202669200_CIW376C406","first-page":"585","article-title":"Nosocomial transmission of multidrug-resistant tuberculosis among HIV-infected persons\u2014Florida and New York, 1988\u20131991","volume":"40","year":"1991","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2024062808202669200_CIW376C407","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/ajcn\/33.2.244","article-title":"A study of malabsorption in intestinal tuberculosis: stagnant loop syndrome","volume":"33","author":"Tandon","year":"1980","journal-title":"Am J Clin Nutr"},{"key":"2024062808202669200_CIW376C408","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJM199212173272514","article-title":"Malabsorption of antituberculosis medications by a patient with AIDS","volume":"327","author":"Berning","year":"1992","journal-title":"N Engl J Med"},{"key":"2024062808202669200_CIW376C409","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1086\/380795","article-title":"Malabsorption of rifampin and isoniazid in HIV-infected patients with and without tuberculosis","volume":"38","author":"Gurumurthy","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2024062808202669200_CIW376C410","doi-asserted-by":"crossref","DOI":"10.1136\/bcr.12.2009.2554","article-title":"Malabsorption of antimycobacterial drugs as a cause of treatment failure in tuberculosis","volume":"2010","author":"Bento","year":"2010","journal-title":"BMJ Case Rep"},{"key":"2024062808202669200_CIW376C411","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1164\/ajrccm.155.1.9001331","article-title":"The incidence of false-positive cultures for Mycobacterium tuberculosis","volume":"155","author":"Burman","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"2024062808202669200_CIW376C412","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/oxfordjournals.aje.a117542","article-title":"Aerial dissemination of pulmonary tuberculosis. A two-year study of contagion in a tuberculosis ward. 1959","volume":"142","author":"Riley","year":"1995","journal-title":"Am J Epidemiol"},{"key":"2024062808202669200_CIW376C413","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1086\/425005","article-title":"The effect of initial drug resistance on treatment response and acquired drug resistance during standardized short-course chemotherapy for tuberculosis","volume":"39","author":"Seung","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2024062808202669200_CIW376C414","first-page":"508","article-title":"Some observations on the genetics of isoniazid resistance in the tubercle bacilli","volume":"104","author":"David","year":"1971","journal-title":"Am Rev Respir Dis"},{"key":"2024062808202669200_CIW376C415","first-page":"687","article-title":"Present aspects of bacterial resistance in tuberculosis","volume":"92","author":"Canetti","year":"1965","journal-title":"Am Rev Respir Dis"},{"key":"2024062808202669200_CIW376C416","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.1993.03510010071032","article-title":"Pitfalls in the care of patients with tuberculosis. Common errors and their association with the acquisition of drug resistance","volume":"270","author":"Mahmoudi","year":"1993","journal-title":"JAMA"},{"issue":"suppl 2","key":"2024062808202669200_CIW376C417","doi-asserted-by":"crossref","first-page":"S241","DOI":"10.1093\/infdis\/jis034","article-title":"New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future","volume":"205","author":"Lienhardt","year":"2012","journal-title":"J Infect Dis"},{"key":"2024062808202669200_CIW376C418","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1164\/rccm.201410-1843OC","article-title":"Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial","volume":"191","author":"Dorman","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"2024062808202669200_CIW376C419","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1164\/rccm.201105-0827WS","article-title":"CDC\/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap","volume":"184","author":"Nahid","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"2024062808202669200_CIW376C420","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1164\/rccm.201402-0363PP","article-title":"Getting personal: perspectives on individualized treatment duration in multidrug-resistant and extensively drug-resistant tuberculosis","volume":"190","author":"Heyckendorf","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"2024062808202669200_CIW376C421","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1056\/NEJMe1410977","article-title":"Shortening treatment for tuberculosis\u2014to basics","volume":"371","author":"Warner","year":"2014","journal-title":"N Engl J Med"},{"key":"2024062808202669200_CIW376C422","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/cid\/civ991","article-title":"Toward earlier inclusion of pregnant and postpartum women in tuberculosis drug trials: consensus statements from an international expert panel","volume":"62","author":"Gupta","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"suppl 1","key":"2024062808202669200_CIW376C423","doi-asserted-by":"crossref","first-page":"69","DOI":"10.5588\/ijtld.15.0616","article-title":"Accelerating clinical drug development for children with tuberculosis","volume":"19","author":"Murray","year":"2015","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024062808202669200_CIW376C424","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1183\/09031936.00043315","article-title":"The role of eHealth and mHealth in tuberculosis and tobacco control: a WHO\/ERS consultation","volume":"46","author":"Falzon","year":"2015","journal-title":"Eur Respir J"},{"key":"2024062808202669200_CIW376C425","article-title":"Introduction and rational use of new drugs and drug regimens for TB treatment","author":"World Health Organization","year":"2015"},{"key":"2024062808202669200_CIW376C426","doi-asserted-by":"crossref","first-page":"407","DOI":"10.7326\/0003-4819-76-3-112-6-407","article-title":"A 62-dose, 6-month therapy for pulmonary and extrapulmonary tuberculosis. A twice-weekly, directly observed, and cost-effective regimen","volume":"112","author":"Cohn","year":"1990","journal-title":"Ann Intern Med"},{"key":"2024062808202669200_CIW376C427","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/cpt.164","article-title":"Antituberculosis drugs in children","volume":"98","author":"Schaaf","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"2024062808202669200_CIW376C428","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(00)02124-3","article-title":"Directly observed therapy and treatment adherence","volume":"355","author":"Volmink","year":"2000","journal-title":"Lancet"},{"key":"2024062808202669200_CIW376C429","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1378\/chest.115.1.218","article-title":"Development of housing programs to aid in the treatment of tuberculosis in homeless individuals: a pilot study","volume":"115","author":"LoBue","year":"1999","journal-title":"Chest"},{"key":"2024062808202669200_CIW376C430","doi-asserted-by":"crossref","first-page":"E29","DOI":"10.1097\/PHH.0b013e3182751d6f","article-title":"Developing and using performance measures based on surveillance data for program improvement in tuberculosis control","volume":"19","author":"Ehman","year":"2013","journal-title":"J Public Health Manag Pract"},{"key":"2024062808202669200_CIW376C431","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.5588\/ijtld.11.0814","article-title":"Predictors of failure in timely tuberculosis treatment completion, United States","volume":"16","author":"Mitruka","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024062808202669200_CIW376C432","first-page":"CD005159","article-title":"Rifabutin for treating pulmonary tuberculosis","author":"Davies","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"2024062808202669200_CIW376C433","first-page":"471","article-title":"Controlled clinical trial of four 6-month regimens of chemotherapy for pulmonary tuberculosis. Second report. Second East African\/British Medical Research Council Study","volume":"114","year":"1976","journal-title":"Am Rev Respir Dis"},{"key":"2024062808202669200_CIW376C434","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/0041-3879(80)90012-4","article-title":"Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis. Second report. Third East African\/British Medical Research Council Study","volume":"61","year":"1980","journal-title":"Tubercle"},{"key":"2024062808202669200_CIW376C435","first-page":"727","article-title":"Controlled trial of 6-month and 9-month regimens of daily and intermittent streptomycin plus isoniazid plus pyrazinamide for pulmonary tuberculosis in Hong Kong. The results up to 30 months","volume":"115","year":"1977","journal-title":"Am Rev Respir Dis"},{"key":"2024062808202669200_CIW376C436","first-page":"417","article-title":"A service program of antituberculosis chemotherapy with five drugs for four months in the treatment of drug addicts and prisoners with pulmonary tuberculosis in Hong Kong. Hong Kong Chest Service\/British Medical Research Council","volume":"122","year":"1980","journal-title":"Am Rev Respir Dis"},{"issue":"3 pt 1","key":"2024062808202669200_CIW376C437","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1164\/ajrccm.156.3.9612016","article-title":"Early bactericidal activity of isoniazid in pulmonary tuberculosis. Optimization of methodology. The DATRI 008 Study Group","volume":"156","author":"Hafner","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"2024062808202669200_CIW376C438","doi-asserted-by":"crossref","first-page":"181","DOI":"10.7326\/0003-4819-84-2-181","article-title":"Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis","volume":"84","author":"Mitchell","year":"1976","journal-title":"Ann Intern Med"},{"key":"2024062808202669200_CIW376C439","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1001\/jama.281.11.1014","article-title":"Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic","volume":"281","author":"Nolan","year":"1999","journal-title":"JAMA"},{"key":"2024062808202669200_CIW376C440","first-page":"991","article-title":"Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study","volume":"117","author":"Kopanoff","year":"1978","journal-title":"Am Rev Respir Dis"},{"key":"2024062808202669200_CIW376C441","first-page":"151","article-title":"Isoniazid hepatitis among pregnant and postpartum Hispanic patients","volume":"104","author":"Franks","year":"1989","journal-title":"Public Health Rep"},{"key":"2024062808202669200_CIW376C442","first-page":"486","article-title":"Isoniazid-related fatal hepatitis","volume":"164","author":"Millard","year":"1996","journal-title":"West J Med"},{"key":"2024062808202669200_CIW376C443","first-page":"560","article-title":"Fatal isoniazid-induced hepatitis. Its risk during chemoprophylaxis","volume":"159","author":"Salpeter","year":"1993","journal-title":"West J Med"},{"issue":"2 pt 1","key":"2024062808202669200_CIW376C444","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1164\/ajrccm\/145.2_Pt_1.494","article-title":"Isoniazid-associated hepatitis deaths: a review of available information","volume":"145","author":"Snider","year":"1992","journal-title":"Am Rev Respir Dis"},{"key":"2024062808202669200_CIW376C445","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1164\/ajrccm\/140.3.700","article-title":"Twenty isoniazid-associated deaths in one state","volume":"140","author":"Moulding","year":"1989","journal-title":"Am Rev Respir Dis"},{"key":"2024062808202669200_CIW376C446","first-page":"458","article-title":"Peripheral neuropathy in tuberculosis patients treated with isoniazid","volume":"68","author":"Lubing","year":"1953","journal-title":"Am Rev Tuberc"},{"key":"2024062808202669200_CIW376C447","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0962-8479(96)90073-8","article-title":"Frequency and type of reactions to antituberculosis drugs: observations in routine treatment","volume":"77","author":"Ormerod","year":"1996","journal-title":"Tuber Lung Dis"},{"issue":"suppl 5","key":"2024062808202669200_CIW376C448","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1097\/01.aids.0000391019.10661.66","article-title":"Adverse events with isoniazid preventive therapy: experience from a large trial","volume":"24","author":"Grant","year":"2010","journal-title":"AIDS"},{"key":"2024062808202669200_CIW376C449","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/00045391-200203000-00012","article-title":"Isoniazid-induced lupus erythematosus presenting with cardiac tamponade","volume":"9","author":"Siddiqui","year":"2002","journal-title":"Am J Ther"},{"key":"2024062808202669200_CIW376C450","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1196\/annals.1422.019","article-title":"Drug-induced lupus","volume":"1108","author":"Borchers","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"2024062808202669200_CIW376C451","doi-asserted-by":"crossref","first-page":"650","DOI":"10.7326\/0003-4819-88-5-650","article-title":"Isoniazid induction of antinuclear antibodies. A prospective study","volume":"88","author":"Rothfield","year":"1978","journal-title":"Ann Intern Med"},{"key":"2024062808202669200_CIW376C452","doi-asserted-by":"crossref","first-page":"520","DOI":"10.7326\/0003-4819-88-4-520","article-title":"Isoniazid and reaction to cheese","volume":"88","author":"Smith","year":"1978","journal-title":"Ann Intern Med"},{"key":"2024062808202669200_CIW376C453","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(85)90038-8","article-title":"Cheese, wine, and isoniazid","volume":"2","author":"Toutoungi","year":"1985","journal-title":"Lancet"},{"key":"2024062808202669200_CIW376C454","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1097\/00007611-198506000-00025","article-title":"Isoniazid interactions","volume":"78","author":"Baciewicz","year":"1985","journal-title":"South Med J"},{"key":"2024062808202669200_CIW376C455","doi-asserted-by":"crossref","first-page":"195637","DOI":"10.1155\/2013\/195637","article-title":"Pregnancy outcomes in HIV-infected women receiving long-term isoniazid prophylaxis for tuberculosis and antiretroviral therapy","volume":"2013","author":"Taylor","year":"2013","journal-title":"Infect Dis Obstet Gynecol"},{"key":"2024062808202669200_CIW376C456","first-page":"1170","article-title":"Effect of isoniazid on reproduction","volume":"108","author":"Ludford","year":"1973","journal-title":"Am Rev Respir Dis"},{"key":"2024062808202669200_CIW376C457","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2165\/00003088-197904060-00001","article-title":"Clinical pharmacokinetics of isoniazid","volume":"4","author":"Weber","year":"1979","journal-title":"Clin Pharmacokinet"},{"key":"2024062808202669200_CIW376C458","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.tube.2010.07.002","article-title":"Cerebrospinal fluid concentrations of antituberculosis agents in adults and children","volume":"90","author":"Donald","year":"2010","journal-title":"Tuberculosis (Edinb)"},{"key":"2024062808202669200_CIW376C459","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1056\/NEJM197307122890208","article-title":"Isoniazid dosage in patients with renal failure","volume":"289","author":"Bowersox","year":"1973","journal-title":"N Engl J Med"},{"key":"2024062808202669200_CIW376C460","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1399-3062.2005.00103.x","article-title":"Prospective randomized control trial of isoniazid chemoprophylaxis during renal replacement therapy","volume":"7","author":"Vikrant","year":"2005","journal-title":"Transpl Infect Dis"},{"issue":"4 pt 1","key":"2024062808202669200_CIW376C461","first-page":"367","article-title":"Experimental models to explain the high sterilizing activity of rifampin in the chemotherapy of tuberculosis","volume":"123","author":"Dickinson","year":"1981","journal-title":"Am Rev Respir Dis"},{"key":"2024062808202669200_CIW376C462","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/jac\/3.2.115","article-title":"Adverse reactions to rifampicin in antituberculosis regimens","volume":"3","author":"Girling","year":"1977","journal-title":"J Antimicrob Chemother"},{"key":"2024062808202669200_CIW376C463","first-page":"45","article-title":"Adverse reactions to rifampicin","volume":"57","author":"Girling","year":"1979","journal-title":"Bull World Health Organ"},{"issue":"suppl 3","key":"2024062808202669200_CIW376C464","doi-asserted-by":"crossref","first-page":"S440","DOI":"10.1093\/clinids\/5.Supplement_3.S440","article-title":"Adverse effects of rifampin","volume":"5","author":"Grosset","year":"1983","journal-title":"Rev Infect Dis"},{"key":"2024062808202669200_CIW376C465","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1136\/bmj.1.5803.765","article-title":"Adverse reactions to daily and intermittent rifampicin regimens for pulmonary tuberculosis in Hong Kong","volume":"1","author":"Aquinas","year":"1972","journal-title":"Br Med J"},{"key":"2024062808202669200_CIW376C466","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1164\/ajrccm.155.5.9154885","article-title":"Rifampin preventive therapy for tuberculosis infection: experience with 157 adolescents","volume":"155","author":"Villarino","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"2024062808202669200_CIW376C467","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/00005792-199911000-00001","article-title":"Hypersensitivity reactions to rifampin. Pathogenetic mechanisms, clinical manifestations, management strategies, and review of the anaphylactic-like reactions","volume":"78","author":"Martinez","year":"1999","journal-title":"Medicine (Baltimore)"},{"key":"2024062808202669200_CIW376C468","first-page":"97","article-title":"Results of a surveillance system for adverse effects in leprosy's WHO\/MDT","volume":"64","author":"Brasil","year":"1996","journal-title":"Int J Lepr Other Mycobact Dis"},{"key":"2024062808202669200_CIW376C469","first-page":"305","article-title":"Higher-dose rifampin for the treatment of pulmonary tuberculosis: a systematic review","volume":"15","author":"Steingart","year":"2011","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024062808202669200_CIW376C470","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1136\/bmj.3.5770.343","article-title":"Potentially serious side effects of high-dose twice-weekly rifampicin","volume":"3","author":"Poole","year":"1971","journal-title":"Br Med J"},{"key":"2024062808202669200_CIW376C471","doi-asserted-by":"crossref","first-page":"82","DOI":"10.7326\/0003-4819-85-1-82","article-title":"Rifampin","volume":"85","author":"Sanders","year":"1976","journal-title":"Ann Intern Med"},{"key":"2024062808202669200_CIW376C472","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1136\/bmj.3.5713.24","article-title":"Rifampicin-induced immune thrombocytopenia","volume":"3","author":"Blajchman","year":"1970","journal-title":"Br Med J"},{"key":"2024062808202669200_CIW376C473","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1378\/chest.96.1.202","article-title":"Thrombocytopenia\u2014a rare but potentially serious side effect of initial daily and interrupted use of rifampicin","volume":"96","author":"Lee","year":"1989","journal-title":"Chest"},{"key":"2024062808202669200_CIW376C474","doi-asserted-by":"crossref","DOI":"10.1136\/bcr.12.2011.5282","article-title":"Do not miss rifampicin-induced thrombocytopenic purpura","volume":"2012","author":"Agrawal","year":"2012","journal-title":"BMJ Case Rep"},{"key":"2024062808202669200_CIW376C475","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1515\/CCLM.1998.041","article-title":"Rifampicin causes false-positive immunoassay results for urine opiates","volume":"36","author":"de Paula","year":"1998","journal-title":"Clin Chem Lab Med"},{"key":"2024062808202669200_CIW376C476","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/S0140-6736(77)91447-7","article-title":"Rifampicin in pregnancy","volume":"2","author":"Steen","year":"1977","journal-title":"Lancet"},{"key":"2024062808202669200_CIW376C477","doi-asserted-by":"crossref","first-page":"532","DOI":"10.2165\/00003088-198510060-00006","article-title":"Cerebrospinal fluid pharmacokinetics of the antituberculosis drugs","volume":"10","author":"Holdiness","year":"1985","journal-title":"Clin Pharmacokinet"},{"key":"2024062808202669200_CIW376C478","doi-asserted-by":"crossref","first-page":"108","DOI":"10.2165\/00003088-197803020-00002","article-title":"Clinical pharmacokinetics of rifampicin","volume":"3","author":"Acocella","year":"1978","journal-title":"Clin Pharmacokinet"},{"issue":"suppl 1","key":"2024062808202669200_CIW376C479","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1093\/clinids\/22.Supplement_1.S50","article-title":"Use of rifabutin in the treatment of pulmonary tuberculosis","volume":"22","author":"Grassi","year":"1996","journal-title":"Clin Infect Dis"},{"key":"2024062808202669200_CIW376C480","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1093\/jac\/dkt446","article-title":"Safety of rifabutin replacing rifampicin in the treatment of tuberculosis: a single-centre retrospective cohort study","volume":"69","author":"Chien","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2024062808202669200_CIW376C481","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1164\/ajrccm.154.5.8912765","article-title":"Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis","volume":"154","author":"McGregor","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"key":"2024062808202669200_CIW376C482","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJM199402103300616","article-title":"Uveitis and pseudojaundice during a regimen of clarithromycin, rifabutin, and ethambutol. MAC Study Group of the Canadian HIV Trials Network","volume":"330","author":"Shafran","year":"1994","journal-title":"N Engl J Med"},{"key":"2024062808202669200_CIW376C483","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1038\/sj.eye.6703016","article-title":"Uveitis associated with concurrent administration of rifabutin and lopinavir\/ritonavir (Kaletra)","volume":"21","author":"Lin","year":"2007","journal-title":"Eye (Lond)"},{"key":"2024062808202669200_CIW376C484","first-page":"1201","article-title":"Polyarthralgia-arthritis syndrome induced by low doses of rifabutin","volume":"26","author":"Le Gars","year":"1999","journal-title":"J Rheumatol"},{"key":"2024062808202669200_CIW376C485","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1001\/archdermatol.2009.221","article-title":"Acute generalized exanthematous pustulosis caused by rifabutin","volume":"145","author":"Chen","year":"2009","journal-title":"Arch Dermatol"},{"key":"2024062808202669200_CIW376C486","article-title":"Mycobutin\/rifabutin [product insert]","year":"2015"},{"key":"2024062808202669200_CIW376C487","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1093\/jac\/34.4.600","article-title":"Concentrations of rifabutin in plasma and cerebrospinal fluid in cynomolgus monkeys","volume":"34","author":"Strolin Benedetti","year":"1994","journal-title":"J Antimicrob Chemother"},{"key":"2024062808202669200_CIW376C488","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1007\/BF00190739","article-title":"Successful treatment of meningoencephalitis caused by Mycobacterium avium intracellulare in AIDS","volume":"72","author":"Malessa","year":"1994","journal-title":"Clin Investig"},{"key":"2024062808202669200_CIW376C489","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1345\/aph.19008","article-title":"Multidrug-resistant tuberculosis meningitis: clinical problems and concentrations of second-line antituberculous medications","volume":"33","author":"DeVincenzo","year":"1999","journal-title":"Ann Pharmacother"},{"issue":"suppl 1","key":"2024062808202669200_CIW376C490","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1093\/clinids\/22.Supplement_1.S15","article-title":"The clinical pharmacokinetics of rifabutin","volume":"22","author":"Blaschke","year":"1996","journal-title":"Clin Infect Dis"},{"key":"2024062808202669200_CIW376C491","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/ndt\/17.3.531-a","article-title":"Pharmacokinetics and dosage adjustment of rifabutin in a haemodialysis patient","volume":"17","author":"Bassilios","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"2024062808202669200_CIW376C492","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0041-3879(84)90024-2","article-title":"The role of pyrazinamide in primary chemotherapy for pulmonary tuberculosis","volume":"65","author":"Girling","year":"1984","journal-title":"Tubercle"},{"key":"2024062808202669200_CIW376C493","first-page":"319","article-title":"Pyrazinamide-isoniazid in tuberculosis","volume":"69","author":"McDermott","year":"1954","journal-title":"Am Rev Tuberc"},{"key":"2024062808202669200_CIW376C494","first-page":"334","article-title":"Observations on the combined use of pyrazinamide (Aldinamide) and isoniazid in the treatment of pulmonary tuberculosis; a clinical study","volume":"69","author":"Campagna","year":"1954","journal-title":"Am Rev Tuberc"},{"key":"2024062808202669200_CIW376C495","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1128\/AAC.01567-09","article-title":"Clinical and toxicodynamic evidence that high-dose pyrazinamide is not more hepatotoxic than the low doses currently used","volume":"54","author":"Pasipanodya","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2024062808202669200_CIW376C496","doi-asserted-by":"crossref","first-page":"56","DOI":"10.2165\/00003495-198223010-00003","article-title":"Adverse effects of antituberculosis drugs","volume":"23","author":"Girling","year":"1982","journal-title":"Drugs"},{"key":"2024062808202669200_CIW376C497","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0041-3879(81)90003-9","article-title":"Serum uric acid concentrations and arthralgia among patients treated with pyrazinamide-containing regimens in Hong Kong and Singapore","volume":"62","author":"Jenner","year":"1981","journal-title":"Tubercle"},{"key":"2024062808202669200_CIW376C498","first-page":"136","article-title":"Pyrazinamide induced hyperuricemia in patients taking anti-tuberculous therapy","volume":"14","author":"Solangi","year":"2004","journal-title":"J Coll Physicians Surg Pak"},{"key":"2024062808202669200_CIW376C499","first-page":"497","article-title":"Epidemiological survey of hyperuricemia as an adverse reaction to antituberculous therapy with pyrazinamide","volume":"83","author":"Taki","year":"2008","journal-title":"Kekkaku"},{"key":"2024062808202669200_CIW376C500","doi-asserted-by":"crossref","first-page":"306","DOI":"10.3109\/s10165-004-0314-5","article-title":"Acute gouty arthritis during pyrazinamide treatment: a case report","volume":"14","author":"Tosun","year":"2004","journal-title":"Mod Rheumatol"},{"issue":"2 pt 1","key":"2024062808202669200_CIW376C501","first-page":"289","article-title":"The occurrence of hyperuricemia during pyrazinamide-isoniazid therapy","volume":"74","author":"Cullen","year":"1956","journal-title":"Am Rev Tuberc"},{"key":"2024062808202669200_CIW376C502","first-page":"143","article-title":"Two years review of cutaneous adverse drug reaction from first line anti-tuberculous drugs","volume":"62","author":"Tan","year":"2007","journal-title":"Med J Malaysia"},{"key":"2024062808202669200_CIW376C503","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.5588\/ijtld.10.0698","article-title":"Outcomes of reintroducing anti-tuberculosis drugs following cutaneous adverse drug reactions","volume":"15","author":"Lehloenya","year":"2011","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024062808202669200_CIW376C504","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S0190-9622(99)70459-7","article-title":"Pyrazinamide-induced lichenoid photodermatitis","volume":"40","author":"Choonhakarn","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"2024062808202669200_CIW376C505","first-page":"1075","article-title":"Pyrazinamide induced photoallergy","volume":"5","author":"Maurya","year":"2001","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024062808202669200_CIW376C506","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1136\/bmj.294.6567.284","article-title":"Penetration of pyrazinamide into the cerebrospinal fluid in tuberculous meningitis","volume":"294","author":"Ellard","year":"1987","journal-title":"Br Med J (Clin Res Ed)"},{"key":"2024062808202669200_CIW376C507","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/0041-3879(69)90020-8","article-title":"Absorption, metabolism and excretion of pyrazinamide in man","volume":"50","author":"Ellard","year":"1969","journal-title":"Tubercle"},{"key":"2024062808202669200_CIW376C508","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1164\/ajrccm\/136.6.1339","article-title":"Five-year follow-up of a controlled trial of five 6-month regimens of chemotherapy for pulmonary tuberculosis. Hong Kong Chest Service\/British Medical Research Council","volume":"136","year":"1987","journal-title":"Am Rev Respir Dis"},{"key":"2024062808202669200_CIW376C509","article-title":"Ethambutol efficacy and toxicity: literature review and recommendations for daily and intermittent dosage in children","author":"World Health Organization","year":"2006"},{"key":"2024062808202669200_CIW376C510","first-page":"34","article-title":"Ethambutol kinetics in patients with impaired renal function","volume":"134","author":"Varughese","year":"1986","journal-title":"Am Rev Respir Dis"},{"key":"2024062808202669200_CIW376C511","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1136\/bjophthalmol-2012-301870","article-title":"Ethambutol-induced optic neuropathy: a nationwide population-based study from Taiwan","volume":"96","author":"Chen","year":"2012","journal-title":"Br J Ophthalmol"},{"key":"2024062808202669200_CIW376C512","first-page":"542","article-title":"Ethambutol induced toxic optic neuropathy in HIV positive patients","volume":"6","author":"Mustak","year":"2013","journal-title":"Int J Ophthalmol"},{"key":"2024062808202669200_CIW376C513","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1136\/pgmj.48.565.667","article-title":"Peripheral neuropathy with ethambutol","volume":"48","author":"Tugwell","year":"1972","journal-title":"Postgrad Med J"},{"key":"2024062808202669200_CIW376C514","first-page":"177","article-title":"Ethambutol in the initial treatment of pulmonary tuberculosis. U.S. Public Health Service tuberculosis therapy trials","volume":"107","author":"Doster","year":"1973","journal-title":"Am Rev Respir Dis"},{"key":"2024062808202669200_CIW376C515","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1378\/chest.66.1.20","article-title":"Ethambutol in pregnancy","volume":"66","author":"Bobrowitz","year":"1974","journal-title":"Chest"},{"key":"2024062808202669200_CIW376C516","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1378\/chest.66.1.25","article-title":"Ethambutol in pregnancy: observations on embryogenesis","volume":"66","author":"Lewit","year":"1974","journal-title":"Chest"},{"key":"2024062808202669200_CIW376C517","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0041-3879(71)90017-1","article-title":"Concentrations of ethambutol in the cerebrospinal fluid after oral administration","volume":"52","author":"Pilheu","year":"1971","journal-title":"Tubercle"},{"key":"2024062808202669200_CIW376C518","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1159\/000220678","article-title":"Ethambutol absorption, excretion and dosage in patients with renal tuberculosis","volume":"15","author":"Strauss","year":"1970","journal-title":"Chemotherapy"},{"key":"2024062808202669200_CIW376C519","doi-asserted-by":"crossref","first-page":"951","DOI":"10.7326\/0003-4819-122-12-199506150-00010","article-title":"Fixed-dose combinations of antituberculous medications to prevent drug resistance","volume":"122","author":"Moulding","year":"1995","journal-title":"Ann Intern Med"},{"key":"2024062808202669200_CIW376C520","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1159\/000334441","article-title":"QT prolongation and torsade de pointes induced by fluoroquinolones: infrequent side effects from commonly used medications","volume":"120","author":"Briasoulis","year":"2011","journal-title":"Cardiology"},{"issue":"suppl 2","key":"2024062808202669200_CIW376C521","doi-asserted-by":"crossref","first-page":"S144","DOI":"10.1086\/428055","article-title":"Antimicrobial safety: focus on fluoroquinolones","volume":"41","author":"Owens","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2024062808202669200_CIW376C522","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1086\/515104","article-title":"Fluoroquinolone toxicity profiles: a review focusing on newer agents","volume":"28","author":"Lipsky","year":"1999","journal-title":"Clin Infect Dis"},{"key":"2024062808202669200_CIW376C523","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1542\/peds.2013-3636","article-title":"Assessment of musculoskeletal toxicity 5 years after therapy with levofloxacin","volume":"134","author":"Bradley","year":"2014","journal-title":"Pediatrics"},{"key":"2024062808202669200_CIW376C524","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.tube.2015.02.037","article-title":"Fluoroquinolones for the treatment of tuberculosis in children","volume":"95","author":"Thee","year":"2015","journal-title":"Tuberculosis (Edinb)"},{"key":"2024062808202669200_CIW376C525","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1097\/INF.0000000000001022","article-title":"Pharmacokinetics and dosing of levofloxacin in children treated for active or latent multidrug-resistant tuberculosis, Federated States of Micronesia and Republic of the Marshall Islands","volume":"35","author":"Mase","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"2024062808202669200_CIW376C526","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0301-2115(95)02524-3","article-title":"Pregnancy outcome after prenatal quinolone exposure. Evaluation of a case registry of the European Network of Teratology Information Services (ENTIS)","volume":"69","author":"Schaefer","year":"1996","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"2024062808202669200_CIW376C527","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.2215\/CJN.01840506","article-title":"Pharmacokinetics of moxifloxacin and levofloxacin in intensive care unit patients who have acute renal failure and undergo extended daily dialysis","volume":"1","author":"Czock","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"2024062808202669200_CIW376C528","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ijantimicag.2008.02.011","article-title":"Pharmacokinetics of levofloxacin after single and multiple oral doses in patients undergoing intermittent haemodialysis","volume":"32","author":"Tsaganos","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"2024062808202669200_CIW376C529","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1093\/jac\/dkn212","article-title":"Single- and multiple-dose pharmacokinetics of intravenous moxifloxacin in patients with severe hepatic impairment","volume":"62","author":"Barth","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"2024062808202669200_CIW376C530","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1086\/598929","article-title":"Safety of fluoroquinolone use in patients with hepatotoxicity induced by anti-tuberculosis regimens","volume":"48","author":"Ho","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2024062808202669200_CIW376C531","first-page":"CD006594","article-title":"Reminder systems and late patient tracers in the diagnosis and management of tuberculosis","author":"Liu","year":"2008","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/63\/7\/e147\/58355824\/ciw376.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/63\/7\/e147\/58355824\/ciw376.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T13:25:46Z","timestamp":1749043546000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/63\/7\/e147\/2196792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,10]]},"references-count":531,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2016,8,10]]},"published-print":{"date-parts":[[2016,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciw376","relation":{},"ISSN":["1537-6591","1058-4838"],"issn-type":[{"value":"1537-6591","type":"electronic"},{"value":"1058-4838","type":"print"}],"subject":[],"published-other":{"date-parts":[[2016,10,1]]},"published":{"date-parts":[[2016,8,10]]}}}